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Alterations to sphingolipid metabolism are associated with increased pulmonary 
inflammation, but the impact of inflammatory mediators, such as neutrophil elastase (NE), on 
airway sphingolipid homeostasis remains unknown. NE is a protease associated CF lung disease 
progression, and can be found in up to micromolar concentrations in patient airways. While 
sphingolipids have been investigated in the context of CF, the focus has been on loss of cystic 
fibrosis transmembrane conductance regulator (CFTR) function. Here, we present a novel 
observation: oropharyngeal aspiration of NE increases airway ceramides in mice. Using a 
previously characterized mouse model of NE-induced inflammation, we demonstrate that NE 
increases de novo ceramide production, which is likely mediated via increased SPTLC2 levels. 
ix 
 
Inhibition of de novo sphingolipid synthesis using myriocin, an SPT inhibitor, decreases airway 
ceramide as well as the release of pro-inflammatory signaling molecules induced by NE. 
Furthermore, in a retrospective study of the sphingolipid content of CF sputum—the largest of its 
type in this patient cohort to date, we investigated the association between NE and sphingolipids. 
There were linear correlations between the concentration of active NE and ceramide, 
sphingomyelin, and monohexosylceramide moieties as well as sphingosine-1-phosphate. The 
presence of Methicillin-resistant Staphylococcus aureus (MRSA) positive culture and female 
gender both strengthened the association of NE and sphingolipids, but higher FEV1 % predicted 
weakened the association, and Pseudomonas aeruginosa had no effect on the association between 
NE and sphingolipids. These data suggest that NE may increase sphingolipids in CF airways as it 
did in our in vivo model, and that this association is stronger in patients that have worse lung 
function, are female, and whose lungs are colonized with MRSA. Modulating sphingolipid 
homeostasis could provide novel pharmacological approaches for alleviating pulmonary 
inflammation. 
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Chapter 1: Introduction 
 
 
 
 
I. An Overview of Cystic Fibrosis. 
Cystic fibrosis (CF) is an autosomal recessive disease that is caused by loss of functioning 
cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is an ion channel, 
responsible for chloride and bicarbonate transport across the plasma membrane. It also regulates 
other ion channels such as the epithelial sodium channel (ENaC) (33, 126, 144). When a genetic 
mutation causes the absence or malfunction of CFTR, a variety of organ systems can be affected, 
depending on the severity of the disease, including the lungs, pancreas, gastrointestinal system, 
sweat glands, and reproductive organs. The most common mutation in Caucasians of Northern 
European descent, the population in which the CF incidence is highest, is c.1521_1523delCTT 
(p.Phe508del or F508del, known colloquially as CFTRΔF508 or  ΔF508), a class II mutation (9, 
18). 
Genetic Basis of Cystic Fibrosis. In total there are currently over two thousand known 
CFTR mutations, which can affect CFTR protein biosynthesis, localization, and functionality (18). 
Disease-causing mutations have been organized into six classes (Class I-VI) (7, 33). In class I 
mutations, functional CFTR protein is not synthesized due to nonsense, frameshift or splicing 
mutations; truncated CFTR are degraded in the endoplasmic reticulum. Thus, no CFTR protein is 
present on cell plasma membranes. Class II mutations likewise yield a loss of CFTR protein on 
plasma membranes; this class of mutation, caused by missense and deletion mutations, produces a 
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misfolded CFTR protein that is subsequently targeted for degradation. Patients with class III 
mutations have gating defects; their cells produce non-functional CFTR that is localized to the 
plasma membrane, but does not conduct ions or regulate other channels. Class IV mutations 
include missense mutations that produce CFTR with decreased chloride conductance— there is 
some residual function, but the channel is inefficient. Patients with class V mutations have fully 
functioning CFTR, but the protein is expressed at a low level due to splicing or missense mutations 
that reduce CFTR biosynthesis. Finally, class VI mutations include missense mutations that 
produce CFTR that is unstable when incorporated into the plasma membrane; thus, there is rapid 
turnover of the protein. Patients with class I, II, and III, mutations on average have a more severe 
CF phenotype, whereas patients with class IV, V, and VI mutations usually have milder disease, 
as they maintain some residual CFTR function (33, 144). 
Cystic Fibrosis Lung Disease. Although many organ systems can be affected depending 
on the severity of the mutations, lung disease is the predominant cause of morbidity and mortality 
in CF (144). Loss of CFTR function has multiple consequences on the airways, including: reduced 
hydration of airway surface liquid, increased airway surface liquid acidity, poor mucociliary 
clearance, and abnormal mucus tethering and function (33). These conditions cause retention of 
abnormal mucus in the airways leading to infections with opportunistic organisms (33). CF lung 
disease is typified by recurring cycles of infection and neutrophilic inflammation (144), leading to 
bronchiectasis— transmural injury to the bronchi with airway inflammation, loss of mucociliary 
clearance, and patulent bronchial regions that retain infected sputum. This progressive airway 
injury leads to gradual loss of lung function, and ultimately respiratory failure that necessitates 
lung transplantation. 
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The dominant pathology in CF is considered to be a failure to clear microbial infections, 
resulting in a toxic pro-inflammatory local microenvironment in the airway (24). Children with 
CF have repeated viral and bacterial respiratory infections, with microbes such as Haemophilus 
influenzae and Staphylococcus aureus, and lung damage is caused both directly and indirectly by 
their bodies’ inflammatory responses (44). As patients age and airway injury progresses, they 
become more susceptible to infection by Gram-negative bacteria. These include environmental 
microorganisms such as Pseudomonas aeruginosa, a prevalent bacterial pathogen in CF, which 
usually only causes disease in immunocompromised patients (24, 91). With repeated infection and 
colonization of the airways by viruses, bacteria— including atypical mycobacteria, and fungi— 
including Aspergillus sp., the patient’s immune system responds with chronic inflammation, which 
contributes to lung damage, leading to more recurrent infections, and subsequently more 
inflammation. 
This vicious cycle of pulmonary infection and inflammation in CF begins early. 
Neutrophils and the serine protease neutrophil elastase (NE) are detectable in patient 
bronchoalveolar lavage (BAL) within three months after birth, although less than half of the infants 
assayed had indications of an active pulmonary infection or a patient history consistent with 
previous infections (103, 109, 121). This implies that several factors contribute to the development 
of the maladaptive inflammation present in CF airways, and indeed there are many studies 
demonstrating that CFTR-deficiency alters immune system function, including aberrant responses 
in inflammatory cells and airway epithelium (17, 23, 43, 126). Likewise, lung damage begins early; 
computed tomography scans have shown that patients with CF can have bronchiectasis within the 
first year of life (120). The development of bronchiectasis in patients with CF is strongly associated 
with inflammatory proteases; neutrophil-derived proteases such as NE, cathepsin G, and proteinase 
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3, as well as macrophage-derived proteases like cathepsin S, and matrix metalloproteinase 9 (75, 
112, 113). In particular, NE is strongly associated with the development of CF (113, 121) and non-
CF bronchiectasis (19). This protease can degrade a variety of proteins (58, 142), including 
opsonins and proteins involved in the innate immune response such as lactoferrin and lysozyme 
(142), which help control infection in the lungs. Furthermore, NE digests components of the 
extracellular matrix (8, 61) and the peptides generated from extracellular matrix degradation also 
function as pro-inflammatory mediators (150). Not surprisingly, NE is also associated with the 
development of emphysema in chronic obstructive pulmonary disease (COPD) (8). 
Neutrophil Elastase and Cystic Fibrosis Lung Disease. CF airways have up to micromolar 
concentrations of NE, which further stimulates an inflammatory response (142) as well as the 
production of MUC5AC, a prominent airway mucin (37, 62, 143, 146) that increases the risk for 
airway mucus obstruction (35). Release of proteolytically active NE injures the airway epithelium, 
triggering the release of pro-inflammatory signaling molecules. In vitro studies have shown that 
NE upregulates IL8 in human airway epithelial cell culture (84). Administering NE to mouse 
airways initiates an inflammatory response, increasing the concentration of pro-inflammatory 
cytokines, including keratinocyte chemokine (KC; murine homologue of CXCL8/IL8) (143) and 
High Mobility Group Box 1 (HMGB1) (47) in murine BAL. HMGB1 is an alarmin that further 
stimulates neutrophilic inflammation, and is another biomarker that correlates with CF lung 
disease severity (20, 73). HMGB1 activation of the Receptor for Advanced Glycation Endproducts 
(RAGE) is a feature of airway inflammation observed in COPD (29). The concentration of 
inflammatory biomarkers like NE and HMGB1 in sputum and BAL predict lung disease 
progression in CF (43, 76, 121). Given that chronic infection and rampant inflammation are 
characteristic of CF lung disease, eliminating pulmonary infections and decreasing inflammation 
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are two of the primary therapeutic approaches to CF (33, 43). While antibiotic therapy is a staple 
of CF therapy, there remains a need for effective anti-inflammatory therapy (33, 43). 
Current and Upcoming Treatments of Cystic Fibrosis Lung Disease. First and foremost 
in the therapeutic repertoire of CF patients is daily airway clearance, to facilitate the removal of 
the abnormal, tenacious mucus from the airways (33, 81). The biological purpose of airway mucus 
is to trap bacterial pathogens and help clear them from the airways (145). In CF, this mechanism 
is hindered; mucus lingers in patient airways, and can even form a mucus plug, clogging the airway 
(11). Patients are given nebulized mucolytics like dornase alfa or therapy with hypertonic saline, 
to facilitate removal of mucus via airway clearance techniques such as chest physiotherapy or the 
high frequency chest wall compression therapy vest (152). Antibiotics become a mainstay of 
treatment early in life, with administration of oral antibiotics for H. influenzae and S. aureus 
bronchitis in children (33, 70). After the first culture of P. aeruginosa, patients are given antibiotics 
aimed at eradicating this pathogen: a three month regimen of oral ciprofloxacin and inhaled colistin 
or one month of inhaled tobramycin (30, 98, 104, 130). Both treatments have comparable efficacy, 
between 70 and 80%, for eliminating P. aeruginosa. Eradication of P. aeruginosa is important, as 
persistent infection with this species is associated with poorer outcomes, including a more rapid 
decline of lung function.  
Patients with CF present with repeated flare-ups or exacerbations of bronchitis, labeled 
pulmonary exacerbations. These are diagnosed using clinical signs and symptoms— including 
increased cough and sputum production— and are usually accompanied by a significant drop in 
lung function (123). Depending on the bacteria present in the airways and the severity of 
symptoms, patients may be treated with oral or intravenous antibiotics and increased airway 
clearance (30, 81). Some patients become severely ill during pulmonary exacerbations, requiring 
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further support with supplemental nutrition and oxygen (33). Effective treatment of exacerbations 
is critical, as an increasing rate of exacerbations is associated with a more rapid decline in patient 
lung function and increased morbidity and mortality (28, 123, 149). Several therapies are used to 
maintain health and reduce the incidence of pulmonary exacerbations: inhaled dornase alfa and 
hypertonic saline, mentioned already as therapeutic staples for CF, as well as a variety of inhaled 
antibiotics, and oral azithromycin (33). 
Since the successful identification of the CFTR gene in 1989, the holy grail of CF 
therapeutics has been correction or replacement of the mutant gene using molecular therapies. 
There has been a recent breakthrough in non-viral CFTR gene therapy in patients with CF, patients 
showed a modest improvement in lung function after a year of therapy— including a statistically 
significant increase of approximately 3.7% in forced expiratory volume in 1 second (FEV1)— but 
the treatment requires further vetting before it can be approved for clinical use (3). There has also 
been an advent of innovative molecular therapies that target specific CFTR defects over the past 
decade. These include “corrector” drugs that increase the localization of CFTR to the plasma 
membrane and “potentiator” drugs that increase CFTR function when on the plasma membrane. 
Ivacaftor, a “potentiator” drug that increases CFTR-mediated chloride transport in most class III 
and IV mutations, thereby restoring mucociliary function in vitro using primary airway epithelial 
cells, is the first of these small molecule therapies to be approved for clinical use (25, 27, 77, 102, 
111, 138, 139, 154). Clinical trials proved that ivacaftor is highly efficacious in patients with class 
III mutations, resulting in an average increase in FEV1 of 10% and reducing the incidence of 
pulmonary exacerbations by 40% (26). A second small molecule therapeutic has been designed 
for patients homozygous for the c.1521_1523delCTT (p.Phe508del) mutation. This therapy is a 
combination of two drugs, a “corrector” and a “potentiator”— lumacaftor and ivacaftor, 
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respectively (138). This combination therapy increased FEV1 by 3% and reduced the frequency of 
pulmonary exacerbations by 30% in patients homozygous for c.1521_1523delCTT (p.Phe508del) 
(12). The modest increase in lung function with this combination therapy appears be due to 
ivacaftor destabilizing “corrector” drugs, resulting in a lower dosage (21, 140). Thus, effective 
molecular therapies for c.1521_1523delCTT (p.Phe508del), the most common CFTR mutation, 
are still needed, as are drugs for Class I mutations to facilitate promoter read-through for premature 
stop codons and to prolong mRNA half-life. 
In CF, acute and chronic neutrophilic inflammation in the lungs contributes to irreversible 
lung damage. Although there are many innovative treatments in development, including gene 
therapy and new CFTR-targeting molecular drugs, investigators have been less successful in 
developing effective anti-inflammatory agents. The steroid prednisone has been shown to increase 
forced vital capacity (FVC) in CF patients, but the many drawbacks of long-term systemic steroid 
use, including increased risk of opportunistic infection, CF related diabetes, and growth failure, 
limit its usefulness in CF (32, 43). Although research has spanned decades, only high-dose 
ibuprofen and chronic oral azithromycin have been identified as effective agents (33). High-dose 
ibuprofen has been shown to slow the rate of lung function decline in teenagers, and reduced 
neutrophil migration into the lungs (63-65). However, this approach is seldom used; the danger of 
gastrointestinal bleeds and renal toxicity necessitate regular tests to determine the levels of 
ibuprofen in patient blood in order to minimize the risk of either complication occurring (43). 
Chronic use of azithromycin may increase risk for resistant atypical mycobacteria and therefore, 
if mycobacteria are cultured from sputum, this therapy is discontinued (122). Current avenues of 
research into inflammation in CF include investigations of compounds that promote rapid 
resolution of infection, and those that would protect against damage mediated by proteases (33). 
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In order to develop more efficacious anti-inflammatory therapy, a more in-depth understanding of 
the factors that contribute to inflammation in CF is necessary, as a potential therapeutic must 
potently reduce inflammation but not interfere with the patient’s ability to resolve infection (43). 
Until a cure for CF is developed, there is a need for efficacious anti-inflammatory therapies, as 
profound airway inflammation is a key driver of progressive lung disease in CF (14, 43, 112). 
 
II. Animal Models of Cystic Fibrosis. 
Translational research uses animal models in order to better understand disease 
pathogenesis, and for the development of novel therapeutics. An ideal animal model would both 
recapitulate the development of human disease and have anatomical and molecular similarities that 
would make it a viable candidate for testing new therapeutics. There are many animal models that 
approximate CF lung disease, including several in mice, and in at least three other species— rats, 
ferrets, and pigs (66). Each animal model has benefits and drawbacks. CF, at its core, is the 
consequence of a genetic mutation that causes the absence or dysfunction of CFTR at the plasma 
membrane; thus, the majority of CF animal models were created by deleting the CFTR gene. 
Genetically Modified Mouse Models. Mouse models are the most prolific and best 
characterized of the animal models of CF currently in existence; they were the first animal models 
of CF to be developed (38). As a whole, mice are relatively easy to work with, and there exist well-
defined methods for genetic manipulation. Consequently, there is an abundance of mouse models 
with CFTR knockout and knock-in mutations, on various genetic backgrounds (66). Recently, the 
popularity of mice with CFTR dysfunction as a model of CF has begun to wane, due to several 
key drawbacks. First, the relatively short lifespan of mice makes them a poor model for studying 
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the progression of chronic diseases, including lung disease in CF (66). Furthermore, unlike 
humans, mice with CFTR dysfunction do not develop spontaneous lung disease, nor do they 
spontaneously develop mucus obstruction or chronic airway bacterial infection (38, 157). In part, 
this is likely due to the fact that mice have an alternative chloride channel that compensates for 
loss of CFTR (66), and lack a proton (H+) cotransporter that is present in pigs and humans that 
increases airway acidity (118). Mice with CFTR dysfunction may be better used to study CFTR 
dysfunction in other organ systems, such as the gastrointestinal tract (24, 144). 
The βENaC mouse model, which overexpresses said epithelial sodium channel, has also 
been touted as a possible model for CF (157). This model is relevant to CF because in epithelial 
cells with mutant CFTR, the ENaC channel is uninhibited and increases influx of sodium causing 
apical surface dehydration (157). These mice more closely approximate spontaneous CF 
pulmonary disease than mice with CFTR dysfunction, presenting with depleted airway surface 
liquid, reduced mucociliary clearance and airway mucus obstruction, as well as chronic airway 
inflammation (157). However, unlike human patients, these mice do not develop spontaneous lung 
infections (157).  
Non-murine Animal Models of Cystic Fibrosis. CFTR-deficient ferrets are a well-
characterized animal model rapidly gaining popularity in CF research (66). These ferrets have 
comparable CFTR expression in their lungs to that observed in humans, and neonatal ferrets with 
CFTR dysfunction develop spontaneous lung infections, which they have difficulty clearing (60, 
128). Like humans with CF, CFTR-deficient ferrets also present with defects in mucociliary 
clearance in the lungs (127). On the other hand, CFTR-knockout ferrets are more difficult and 
costly to maintain than mice. These animals have a high incidence of meconium ileus, with up to 
75% of animals dying within the first two days of life without surgical intervention (128). 
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CF rats are a relatively new model, initially described by Tuggle et al. in 2014 (136). In 
terms of pulmonary phenotype, CFTR knockout rats have decreased chloride conductance, 
decreased airway surface liquid, and increased intracellular mucus in the airways. Like many other 
animal models of CF (66), CFTR knockout rats do not have baseline differences in inflammation 
at birth, when compared to wild-type littermates (136). Much remains unknown regarding CFTR-
deficient rats, including whether they recapitulate CF pulmonary disease as they age and their 
susceptibility to bacterial infection. The major drawback of the CF rat model is that its 
characteristics have yet to be fully explored. 
Within the past decade, we have seen the advent of larger animal CF models. CFTR 
knockout and p.Phe508del homozygous pigs were described in 2008 (108). Pigs have a long life 
span, allowing for more in-depth studies of disease pathogenesis, and longitudinal trials for 
describing the effects of long-term use of different therapies (66). Like human patients, CF pigs 
develop lung disease spontaneously, although they demonstrate comparable levels of neutrophils 
and inflammatory markers as their wild-type littermates. Additionally, newborn pigs with CFTR 
dysfunction cannot successfully clear S. aureus infection (108, 125). On the other hand, pigs are a 
far more difficult model to work with. They are significantly more expensive for husbandry and 
care. Newborn pigs with CFTR-deficiency also require significant veterinary care early in life; 
100% of CFTR-knockout pigs develop meconium ileus, necessitating surgery for the animals to 
survive (79). 
A Mouse Model of Neutrophil Elastase-induced Inflammation. In summary, none of the 
mouse models discussed recapitulate the clinical course of lung disease seen in human patients. 
They do not demonstrate the spontaneous infections and inflammation that are the clinical 
characteristics of CF lung disease in humans. On the other hand, non-murine animal models of 
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CF, while more representative than mice, are also more burdensome both economically and in 
terms of manpower needed to maintain them.  
To investigate the role of NE in regulating inflammation in CF airways, we chose to use a 
previously characterized mouse model of NE-induced inflammation and goblet (mucous) cell 
metaplasia (47, 143). This model is intended for investigating the effects of NE, and the 
downstream inflammatory signals triggered by NE, on the airway. Three doses of proteolytically 
active NE derived from human sputa, at a concentration comparable to that seen in the airways of 
patients with CF and chronic bronchitis (84, 124), are delivered by oropharyngeal aspiration on 
days 1, 4, and 7 (143). NE stimulates a robust inflammatory response in mouse lungs; within 24 h 
after the installation of the last NE dose (day 8), there is an influx of macrophages, neutrophils, 
and eosinophils and increasing airway concentrations of pro-inflammatory cytokines, including 
KC (143) and HMGB1 (47), readily detectible in mouse BAL. Goblet cell metaplasia, which 
begins on day 8, peaks on day 11 (143). This model has been useful for investigating NE-induced 
pulmonary oxidative stress (78), inflammatory mediators regulated by NE (47, 143), and has been 
used to test anti-protease and anti-inflammatory therapies (47). However, this model is not CFTR-
deficient, and therefore not useful for evaluating the impact of loss of CFTR on innate immune 
function or overexuberant inflammation in the lungs. While our chosen model has many of the 
same benefits and drawbacks as other mouse models, it focuses on the effects of NE and 
neutrophilic inflammation— a crucial factor in CF lung disease. Because sphingolipids are 
reported to regulate inflammation (42, 74, 119) and the host response to infection (96, 131), we 
sought to determine whether alteration in airway sphingolipids were involved in NE-induced 
airway inflammation in vivo. 
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III. Sphingolipids and Inflammatory Lung Disease 
Sphingolipid Structure and Biosynthesis. Sphingolipids are complex, bioactive lipids; 
they are canonically known as components of plasma membranes and extracellular fluids, but have 
more recently been recognized to be signaling molecules that can act both intra- and extracellularly 
(42). The sphingolipid ceramide forms the backbone of all other sphingolipids (Figure 1). 
Ceramide is composed of a sphingoid base, a long-chain amino alcohol, and an amide-linked fatty 
acid of various chain lengths (137). In mammalian cells, sphingosine (18-20 carbon chain lengths) 
and non-hydroxy fatty acids (typically, 16-24 carbon chain lengths) are the predominant 
constituents of ceramide (137). Sphingoid bases like sphinganine (dihydrosphingosine) and 
phytosphingosine (1,3,4-trihydroxydihydrosphingosine) and other fatty acids (e.g. 2-hydroxy fatty 
acids) can also be components of ceramide in mammals, but these are significantly rarer (137). 
Ceramide can be produced through three major pathways: 1) de novo sphingolipid 
biosynthesis, 2) sphingomyelin hydrolysis by sphingomyelinases (SMases), and 3) degradation of 
complex sphingolipids (Figure 2) (74, 137). The first, rate-limiting step of de novo sphingolipid 
synthesis is catalyzed by serine palmitoyltransferase (SPT), a multimeric protein, predicted to be 
an octamer, consisting of three major subunit types— SPT long chain 1, 2, and 3 (SPTLC1-3, 
LCB1-3) (57). Regulation of SPT expression and modulators of SPT activity are under 
investigation but currently poorly understood (15, 16, 41, 89). It has been postulated that SPT 
activity could be affected by the ratio of SPTLC2 to SPTLC3, with SPTLC2 responsible for the 
production of d18:1/18:0 and long chain ceramides, including d18:1/22:0, d18:1/24:0, and d18:1/24:1 (68), and 
SPTLC3 responsible for the production of shorter chain ceramides like d18:1/14:0 and d18:1/16:0 (56). 
Orosomucoid-like protein isoform 3 (ORM (yeast)-like protein isoform 3, ORMDL3) (15, 89) and 
Reticulon-4 (RTN4; also referred to as Neurite OutGrowth inhibitor, NOGOB) (16, 115) are 
13 
 
known negative regulators of SPT activity. Additionally, downregulation of microRNA miR-137, 
181c, -9 or 29a/b, increases SPT expression and thus activity (41). Ceramide synthases (CerS), of 
which there are six different isoforms (CerS1-6, LASS1-6), are responsible for forming the 
different chain lengths of amide-linked fatty acids on ceramide (Table 1). CerS show both 
substrate and tissue specificity, with the predominant species in the lungs reported to be CerS2 
(93). Interestingly, different chain lengths of fatty acids on ceramide are not only generated by 
different CerS, but also have different biological activities (137). Regulation of CerS activity is 
currently under investigation; recent data indicate that CerS activity can be modulated post-
translationally by the formation of hetero-and homodimers between different CerS (e.g. CerS2 and 
CerS5) (67). In cells, both SPT and CerS can be localized to the endoplasmic reticulum, where de 
novo sphingolipid occurs. In the SMase pathway, sphingomyelin is hydrolyzed into ceramide via 
the action of SMases. Six isoforms of SMase have been identified in mammalian cells— acid 
SMase, four varieties of neutral SMase, and alkaline SMase. SMases that produce ceramide 
associated with signaling are associated with the plasma membrane and with the endoplasmic 
reticulum (137). Finally, the third pathway to ceramide production is the scavenger pathway, 
wherein complex glycosphingolipids are broken down into sphingosine via lysosomal enzymes; 
ceramide is again synthesized from sphingosine via CerS (92). 
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Figure 1. Composition of d18:1/14:0 ceramide. A ceramide consists of a sphingoid base such as 
sphingosine ranging from 18 to 20 carbon chain lengths (an 18:1 sphingosine, above, framed in 
blue), and an amide-linked fatty acid, usually between 14 and 36 carbon chain lengths (14:0, above, 
framed in red). 
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Figure 2. Pathways to ceramide synthesis. De novo biosynthesis of ceramide is a multi-step 
process. The first step is catalyzed by SPT, which combines serine and palmitoyl-CoA into 3-
ketosphinganine. Next, 3-ketosphinganine is reduced to sphinganine (dihydrosphingosine) via a 
reductase. Sphinganine is converted to dihydroceramide by a CerS. Finally, dihydroceramide is 
converted by a desaturase to ceramide. In the sphingomyelinase pathway, sphingomyelin, a major 
plasma membrane component, is degraded by SMases to produce ceramide. The salvage pathway 
involves the breakdown of complex sphingolipids into sphingosine in lysosomes, followed by 
conversion of sphingosine to ceramide via CerS (74, 137). 
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Table 1. Ceramide synthases produce ceramides using acyl-CoA of different chain lengths, 
resulting in ceramides with different fatty acid chain lengths. 
Ceramide Synthase Acyl Chain Length Specificity 
CerS1 18-carbon 
CerS2 20-, 22-, 24-, 26-carbon 
CerS3 22-, 24-, 26-carbon 
CerS4 18-, 20-carbon 
CerS5 16-carbon 
CerS6 14-, 16-carbon 
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Sphingolipids and Inflammation. Regardless of the pathway producing the sphingolipid, 
these bioactive lipids are important contributors to the inflammatory response— ceramide, 
ceramide-1-phosphate (C1P), and sphingosine-1-phosphate (S1P) regulate inflammation when 
released by cells (74, 119). Ceramide, in particular, is considered to be pro-inflammatory, and 
recent findings indicate that ceramide can initiate a signaling cascade via the inflammasome, 
eventually resulting in the activation of caspase 1, and the release of pro-inflammatory cytokines 
including IL1β and KC (132). Ceramides of various chain lengths are induced by different 
stressors, and consequently facilitate cell and tissue-specific responses (48). For example, in the 
airway epithelium, neutral SMase is upregulated by oxidative stress, e.g. cigarette smoke, and this 
change is associated with increased ceramide levels in COPD (22). On the other hand, inhibition 
of vascular endothelial growth factor receptors stimulated de novo sphingolipid synthesis and 
facilitates the overproduction of acid SMase in rodent models of emphysema (95). Finally, direct 
intratracheal administration of an analogue of d18:1/12:0 ceramide into murine airways triggers the 
synthesis of long-chain ceramides, septal apoptosis and emphysema (95). In the lungs, 
sphingolipid metabolism is closely related to inflammation, and increases in ceramide favor the 
development of pathological inflammation (42). Importantly, several sphingolipid species affect 
neutrophil biology (34). In ulcerative colitis, CerS2 and CerS6 have opposing regulatory effects 
on neutrophil chemotaxis into tissue (34). In the intestine, several sphingolipids affect various 
neutrophil functions including phagocytosis, generation of oxidants, and production of neutrophil 
extracellular traps (34). 
Sphingolipids and Inflammatory Respiratory Diseases. Among the earliest connections 
discovered between pulmonary inflammation and increased levels of sphingolipids was the 
association between acute respiratory distress syndrome (ARDS)/acute lung injury (ALI) and 
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ceramide overexpression. Ceramide and glycosphingolipids are known to be increased in the BAL 
of patients with ARDS (106). Likewise, in pulmonary edema, increased acid SMase activity leads 
to higher levels of ceramide in fluids and tissue (45), and pharmacological inhibition of SMase 
activity or genetic ablation of acid SMase in animal models decreased pulmonary inflammation 
and edema (141). 
Sphingolipids in Asthma. Sphingolipids have been shown to contribute to the development 
of lung diseases typified by chronic inflammation. Asthma, a lung disease that varies in severity, 
is characterized by chronic airway inflammation, increased mucus production, and airflow 
obstruction (87). Patients with asthma have been found to have elevated levels of S1P in their 
airways; this sphingolipid metabolite has been shown to stimulate airway hyperresponsiveness and 
inflammation in asthma models (86, 135). Likewise, animal models of allergic asthma demonstrate 
increased airway S1P and ceramide (85, 97). De novo ceramide synthesis has also been linked with 
asthma; a single nucleotide polymorphism that results in altered expression of ORMDL3, a 
negative regulator of SPT activity, has been linked to childhood asthma by a Genome-Wide 
Association Study (80). Interestingly, inhibiting sphingosine kinase activity, and therefore S1P 
production, mitigates airway inflammation in rodent models of asthma (85, 97). FTY720, an 
analogue of sphingosine, inhibits the activity of sphingosine kinase and interacts with S1P 
receptors after it is phosphorylated (74). FTY720 has been shown to decrease ceramide levels in 
the lungs and concurrently alleviate airway hyperresponsiveness, inflammation, and mucus 
production in an allergic mouse models of asthma (89). 
Sphingolipids in Chronic Obstructive Pulmonary Disease. In COPD, a disease 
characterized by chronic inflammation in the airways, sphingolipid moieties facilitate the onset 
and progression of lung disease (42). In emphysema, ceramide accumulates in alveolar epithelia 
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and induces alveolar epithelial cell apoptosis and inflammation (42, 94). Analysis of sputum 
samples from patients with COPD reveals an increase in various sphingolipids, including 
ceramides, in patients who smoked compared with nonsmoking COPD patients (133). 
Environmental stresses, such as cigarette smoke, hypoxia, and chronic inflammation, 
downregulate CFTR expression; therefore, it is possible that loss of CFTR may be a shared 
mechanistic link driving the progression of lung disease in COPD and CF (101). However, there 
is a paucity of data published on airway sphingolipids in patients with CF, therefore, it is not yet 
known whether there are similarities between the airway sphingolipid profiles in COPD and CF. 
Sphingolipids in Cystic Fibrosis. The maladaptive, hyperinflammatory response to airway 
infection characteristic of CF lung disease is associated with altered lipid homeostasis, including 
sphingolipids. Studies of sphingolipid imbalance in CF have focused on changes that result from 
CFTR dysfunction (10, 132). In human airway and nasal cells that have dysfunctional CFTR (51, 
96, 132), alterations in ceramide expression are attributed to loss of CFTR activity. However, 
examining sphingolipid biosynthesis in experiments with human airway epithelial cell lines has 
yielded contradictory results, and different pathways have been implicated as responsible for 
changes in sphingolipid expression. Hamai et al. demonstrated that decreasing CFTR expression 
through genetic manipulation or expressing mutant p.Phe508del in airway epithelial cell lines 
results in increased intracellular sphingosine, sphinganine, and sphingomyelin, as well as d18:0/16:0, 
d18:1/22:0, d18:1/24:0, and d18:1/26:0 ceramide, with concurrent decreases in d18:1/18:1 and d18:0/18:0 
ceramide (51). As decreased expression of CFTR was also associated with increased protein 
SPTLC1, the authors link CFTR dysfunction and de novo sphingolipid biosynthesis (51). In 
contrast, Yu et al. observed that decreased or mutant CFTR affects the function of acid SMase in 
human airway epithelial cell lines, with CFTR-deficient cells expressing less acid SMase and 
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producing less ceramide in response to P. aeruginosa infection (156). A similar defect in acid 
SMase activity in response to P. aeruginosa was observed in CFTR knockout mice (156). 
There are several mouse models with different Cftr mutations which display varying levels 
of deficiency in Cftr function (158), and, much like experiments with human airway epithelial cell 
lines, disparate results regarding changes in ceramide levels. One variable is whether in Cftr-null 
mice, the deficiency in gut Cftr is corrected by replacement with intestinal fatty acid binding 
protein-driven human CFTR. The impact of gut correction is that these mice do not require a 
special cholesterol rich diet and the change in diet affects sphingolipid homeostasis (132). 
Teichgräber et al. tested two different strains of Cftr-deficient, gut-corrected mice (CFTRtm1Unc-
Tg(FABPCFTR) and B6.129P2(CF/3)-CFTRTgH(neoim)Hgu); in both mouse models, loss of Cftr appears 
to result in increased acid SMase and decreased ceramidase activity, which increases ceramide 
production and decreases breakdown, respectively (132). Ceramide accumulation and 
inflammation in gut-corrected Cftr-deficient mice can be abrogated by decreasing the activity of 
acid SMase, whether by knocking down expression of the protein though genetic manipulation or 
through the use of SMase inhibitors (132). Guilbault et al., in contrast, observed decreased 
ceramides in the lung tissue of Cftr-knockout mice; treatment with fenretinide induced ceramide 
synthesis and corrected this defect, also improving the ability of these mice to clear P. aeruginosa 
pulmonary infections (49). Fenretinide has multifactorial effects on de novo ceramide synthesis, 
inducing SPT activity but also inhibiting conversion of dihydroceramide to ceramide and 
downregulating CerS5 expression (40, 155). Although studies in CFTR-deficient mouse models 
report both increased (46) and decreased (49) ceramide in mouse airways, normalizing pulmonary 
ceramide levels in these animals decreases pro-inflammatory signals (46, 49). 
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The impact of sphingolipids on CF lung disease in humans remains largely unexplored. To 
the extent of our knowledge, limited data are available regarding the sphingolipid content in the 
sputum and lung tissue of patients with CF. What data are available indicate that, like in COPD 
(92, 93), increased levels of several ceramide moieties are associated with poorer lung function 
and increased inflammation (133). Brodlie et al. analyzed the ceramide content of late-stage 
diseased CF lungs from lung transplant recipients, describing an increase in ceramide in the lower 
airways (13). They observed correlations between d18:1/16:0, d18:1/18:0, and d18:1/20:0 ceramide moieties 
and markers of neutrophilic inflammation— NE and myeloperoxidase (13). In CF versus non-CF 
sputum, Quinn et al. observed that sphingomyelin d18:1/14:0, d18:1/15:0, d18:1/16:1, and d18:1/16:0 as well 
as two d18:1/16:0 glycosphingolipids, tetraglycosylceramide and lactosylceramide were elevated 
(100). In a single subject with CF followed for 4.2 years, ceramide was consistently increased 
during treatment of pulmonary exacerbation (99). There are also limited data that indicate acid 
SMase may play a role in increased ceramide in patients with CF. Two early Phase II clinical trials 
reveal that treating patients with CF with amitriptyline (1, 83, 107), an acid SMase inhibitor, 
marginally increases lung function (FEV1 % predicted). However, these trials had very limited 
numbers of subjects, and await confirmation in larger prospective trials. 
 
IV. Hypothesis and Specific Aims. 
Ceramide is a bioactive sphingolipid, a driver of pulmonary inflammation (74) that also 
negatively affects host antimicrobial responses (117, 132). In the current paradigm, ceramide 
accumulation in CF is attributed to dysregulation of sphingolipid homeostasis due to the loss of 
functional CFTR (132). However, elevated levels of ceramide have been correlated with 
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neutrophilic inflammation in lung tissue from patients with CF and in sputum from patients with 
COPD (13, 133), and is likewise increased in airway diseases typified by acute inflammation (106, 
141). Additionally, administration of the protease porcine pancreatic elastase induces de novo 
synthesis of ceramide in a mouse model of emphysema (134). NE, a serine protease and major 
inflammatory mediator in the CF airway, is a biomarker for lung disease progression in patients 
(113, 121). We hypothesize that NE and ceramide create an inflammatory feedback loop, wherein 
NE increases ceramide biosynthesis, which subsequently potentiates neutrophilic inflammation, 
thereby increasing local NE levels, resulting in a correlation between NE activity and ceramide in 
the lungs. In order to test this hypothesis, we proposed the following aims. In Aim 1, we tested 
whether NE increases airway ceramide levels in Balb/C mice, using a mouse model of intratracheal 
NE administration that causes airway inflammation (47). In Aim 2, we determined if inhibiting 
ceramide biosynthesis mitigates NE-induced inflammation in Balb/C mice. Finally, in Aim 3, we 
analyzed sputum samples collected from subjects with CF to determine whether levels of active 
NE in sputum correlate with airway ceramide levels, and whether these levels vary with clinical 
status. This dissertation alters the current CFTR-centric paradigm of the regulation of sphingolipid 
homeostasis in the lungs of patients with CF, and tests whether altered sphingolipid homeostasis 
is required for NE-induced airway inflammation.   
25 
 
 
 
 
 
 
Chapter 2: Methods 
 
 
 
 
I. A Mouse Model of Neutrophil Elastase-induced Inflammation. 
A mouse model of NE-induced inflammation and mucous (goblet) cell metaplasia has been 
developed and characterized in both male C57BL/6J and Balb/C mice. Male Balb/C mice, 6 to 8 
weeks of age, (Jackson Laboratories, Bar Harbor, ME) were maintained and treated as per an 
approved IACUC protocol at Virginia Commonwealth University (VCU) (AD10000870). On days 
1, 4 and 7, following isoflurane anesthesia, mice were administered NE (50μg, 42μM; SE563, 
Elastin Products, Owensville, MO) or vehicle control by oropharyngeal aspiration (Figure 3). To 
test the effect of the inhibition of de novo sphingolipid synthesis, mice were administered myriocin 
(SPT inhibitor, 0.3mg/kg; 35891-70-4; Cayman Chemicals, Ann Arbor, MI (89, 134)) or a vehicle 
control by intraperitoneal (IP) injection 2h prior to aspiration of NE or vehicle control on days 1, 
4 and 7. In all experiments, mice were euthanized with Euthasol (200-071; Virbac, Carros, France) 
at 4h, 8h, or 24h (day 8) following the final aspiration dose on day 7. After euthanasia, mice were 
carefully dissected. First, the thoracic cavity was opened, the sternum and ribs resected to expose 
the heart and lungs, and the diaphragm carefully cut. Using a 1mL syringe, blood was collected 
from the right and left ventricles, and diluted 1:5 in 0.5M ethylenediaminetetraacetic acid (EDTA). 
To isolate plasma from blood, samples were centrifuged for 10 min at 1500 ×g at 4°C, and the 
supernatant aliquoted and stored at -80°C. The cut to the chest was then extended to the neck, 
carefully exposing the trachea, and a thread looped underneath it. An intravenous catheter 
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(24G×3/4” Exel Safelet Catheter) was inserted into the trachea, the needle slowly removed, and 
looped thread tied securely to hold the catheter in place inside the trachea. A 1mL syringe, 
containing sterile normal saline (1mL), was attached to the catheter. The lungs were perfused with 
saline, and BAL extracted from the lungs. Lungs were extracted from the thoracic cavity and 
separated, with one lung snap-frozen in liquid nitrogen and the second stored in formalin. 
Bronchoalveolar Lavage, Cell Counts, Cytospins. Collected BAL samples were 
centrifuged (500×g, 10 min), and the supernatant, to be used for cytokine and sphingolipid 
analyses, was aliquoted and stored at -80°C. The cell pellet was re-suspended in 0.5mL of ACK 
(Ammonium-Chloride-Potassium) Lysing Buffer to lyse any red blood cells present, mixed 
thoroughly, and centrifuged (500×g, 10 min). The lysing buffer was removed, and the cell pellet 
re-suspended in 0.1mL saline. A sample of 10µL of BAL cell pellet was aliquoted and mixed with 
trypan blue for cell count with a haemocytometer. A sample of 1×105 cells per slide were used for 
each cytospin and centrifuged (800rpm, 3min), with two slides prepared per mouse. Slides were 
air-dried overnight prior to staining with PROTOCOL HEMA3 Fixative and Solutions, as per 
manufacturer’s instructions (122-911; Fisher Scientific, Hampton, NH). In summation, slides were 
dipped in Fixative solution (5×), followed by Stain 1 (5×), and Stain 2 (5×), with excess solution 
allowed to drain after every immersion. Slides were rinsed in distilled water and air-dried prior to 
mounting with VectaMount Permanent Mounting Medium (H-5000; Vector Laboratories, 
Burlingame, CA), and applying a glass coverslip. 
Cytokine Quantitation by Sandwich ELISA. The concentration of KC in BAL fluid was 
measured by sandwich ELISA (MKC00B; R&D Systems, Minneapolis, MN), per the 
manufacturer’s instructions. In summation, a mouse KC standard stock solution was reconstituted 
with calibrator diluent (1000 pg/mL stock) and serially (1:2) diluted in Calibrator Diluent with the 
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final solutions being as follows: 1000 pg/mL, 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.6 pg/mL, 
31.3 pg/mL, 15.6 pg/mL, and 0 pg/mL (diluent alone). A volume of 50µL Assay Diluent and 50µL 
of standard, control, or sample was added to each well and mixed thoroughly. Microtiter strips that 
were in use were covered with provided adhesive and incubated at room temperature for 2h under 
gentle agitation. After incubation, samples were aspirated, and the wells thoroughly washed five 
times with Wash Buffer (400µL per well, per wash). Mouse KC Conjugate (100µL) was added to 
each well, the well covered with a new adhesive strip, and the plate incubated at room temperature 
for 2h under gentle agitation. After incubation, samples were again aspirated, and the wells 
thoroughly washed five times with Wash Buffer (400µL per well, per wash). Next, 100µL of 
Substrate Solution were added to each well, mixed gently, and incubated for 30 min, in the dark, 
at room temperature. Finally, 100µL Stop Solution were added to end the reaction, mixed 
thoroughly, and the optical density at λ=570 nm for each well determined using a 
spectrophotometer. Concentrations of KC in each sample were determined using the standard 
curve. 
Lung Homogenization. Frozen lungs were manually homogenized with a mortar and 
pestle and suspended in 300-500µL of either QIAzol (15596026; ThermoFisher Scientific, 
Waltham, MA), for later processing for RNA analysis or in a total cell lysis buffer (50mM Tris, 
pH 7.5, 150mM NaCl, 1mM EDTA, 1mM dithiothreitol (DTT), 1mM phenylmethanesulfonyl 
fluoride (PMSF), 1× protease inhibitor (P8340) , and 1× phosphatase inhibitor (P5726),  Sigma-
Aldrich, St. Louis, MO) for protein analysis.  
Sample Processing for Q/RT-PCR. Total RNA was isolated from tissue homogenate by 
using QIAzol (15596026; ThermoFisher Scientific, Waltham, MA) and then processed as per 
manufacturer’s instructions. In summation, after the sample was homogenized and QIAzol added, 
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for every mL of QIAzol, 0.2 mL of chloroform was added to the sample. After capping the tube 
securely, samples were vigorously shaken of 15-20 sec, then allowed to sit for 3 min at room 
temperature. Samples were centrifuged at 12000×g at 4°C, for 15 min. The aqueous phase, present 
at the top of the tube, was transferred to a new microfuge tube, and 0.5mL (per initial mL of QIAzol 
used) of isopropanol and 5µL of glycogen was added to each sample and mixed thoroughly by 
vortexing. Samples were incubated at -20°C overnight, and then centrifuged at 12000×g at 4°C, 
for 10 min. The supernatant was aspirated and discarded, with care taken not to disturb the pellet. 
A volume of 75% ethanol (1mL for every mL of QIAzol Lysis Buffer used) was added, and the 
sample centrifuged at 7500×g for 5 min, at 4°C. The supernatant was removed, and the sample 
spun again at 7500×g for 5 min, at 4°C so that any remaining ethanol could be aspirated. The RNA 
pellet was briefly air-dried at room temperature, for no more than 5-10 min, and then dissolved in 
25µL of diethyl pyrocarbonate (DEPC)-treated water, warmed to 55-60°C for 10 min. RNA was 
quantified by determining sample absorbance at λ=260/280, and diluted for DNAse treatment.  
A sample of 5µg RNA was treated with DNase (18068-015, ThermoFisher Scientific, 
Waltham, MA), according to the manufacturers protocol. In summary, 5µg RNA was combined 
with 5µL DNase I Reaction Buffer and 5µL DNase I (Amplification Grade) and brought to a 
volume of 50µL with DEPC-treated water. Each sample was mixed thoroughly and then incubated 
for 15 min at room temperature. Next, 5µL of 25mM EDTA was added to each sample to stop the 
reaction, and samples were incubated at 65°C for 10 min. DNase-treated RNA was quantified by 
determining sample absorbance at λ=260/280 and diluted in DEPC-treated water for Q/RT-PCR. 
Q/RT-PCR was performed on a SDS 7300 machine (Applied Biosystems). In summary, 5µL of 
diluted RNA was combined with 15µL of master mix, consisting of: 10µL qScript XLT One-Step 
RT-qPCR ToughMix, ROX (2X) (95133-500, Quanta Biosciences), 1µL 20X TaqMan Assay 
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Reagent (primer and probe mix), and 4µL DEPC-treated water in each sample well. Universal 
amplification conditions were used: 50°C for 30 min, then 95°C for 2 min, and finally 40 cycles 
of 95°C for 15 sec followed by 60°C, 1 min. 
Q/RT-PCR was performed to determine if administering NE modulated the expression of 
genes relevant to sphingolipid synthesis (Table 2) in mouse lungs. Mouse β-actin (4352341E; 
ThermoFisher Scientific, Waltham, MA) was used as an endogenous control. The relative level of 
gene expression was calculated using the ΔΔCT method, which represents the fold difference in 
gene expression, corrected for expression of an endogenous control gene, and then normalized to 
control treated samples. 
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Table 2. List of target genes assayed by Q/RT-PCR. 
Target Gene Primer IDa 
SPTLC1 Mm00447343_m1  
SPTLC2 Mm00448871_m1 
β-actin Mm00607939_s1 
 
a Primers acquired from ThermoFisher Scientific (Waltham, MA). 
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Figure 3. Overview of the treatment protocol for NE aspiration. Mice received 3 doses of NE, 
with a dose delivered via oropharyngeal aspiration on days 1, 4, and 7. After euthanasia, at 4, 8, 
or 24 h (day 8) after final NE dose, lungs and BAL were harvested. 
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Sample Processing for Western Blot. After homogenization, samples were sonicated three 
times for 15sec and incubated with agitation for 1h, at 4°C. Homogenates were clarified by 
centrifugation (16,000×g, 4°C, 30 min). The resulting supernatant was the lung lysate protein, 
ready for quantitation and storage at -80°C in single use aliquots for western blot. A DC Protein 
Assay (5000116; BioRad, Hercules, CA) was used to determine sample protein concentrations, as 
per the manufacturer's instructions. 
Western Blot. Mouse whole lung lysate (50μg) or BAL (40μL) were separated by 
electrophoresis on a 4-20% SDS-PAGE gel (17000436; BioRad Hercules, CA), transferred to a 
nitrocellulose membrane, and blocked with 5% nonfat milk in 15mM Tris, 150mM NaCl, 0.1% 
Tween-20 (TBST). Membranes were incubated in mouse monoclonal anti-HMGB1 (sc-56698; 
1:5000 in 5% Milk/TBST; SantaCruz Biotechnology, Dallas, TX), rabbit polyclonal anti-SPTLC1 
(15376-1-AP; 1:5000 in 5% Milk/TBST; Proteintech, Chicago, IL), rabbit polyclonal anti-
SPTLC2 (ab23696; 0.5µg/mL in 5% Milk/TBST; AbCam, Cambridge, United Kingdom), mouse 
monoclonal anti-NOGO (sc-271878; 1:1000 in 5% Milk/TBST; SantaCruz Biotechnology, Dallas, 
TX) or anti-ORMDL3 (ABN417; 1:1000 in 2%BSA/TBST; Millipore, Billerica, MA) primary 
antibody overnight at 4°C, followed by either HRP-conjugated goat anti-mouse antibody (SC-
2005, SCBT, Dallas, TX) or HRP-conjugated goat anti-rabbit antibody (7074,Cell Signaling 
Technology, Danvers, MA). Antigen-antibody complexes were visualized by chemiluminescence 
(ECL Plus; RPN2132; GE Healthcare Life Sciences, Piscataway, NJ), as per the manufacturer’s 
instructions. Membranes with whole lung lysate were washed three times, 10min each, in TBST 
and re-probed with a monoclonal antibody against β-actin (A5441; 1:5000 in 5% Milk/TBST; 
Sigma, St. Louis, MO) to confirm equivalent protein loading. Densitometry of target bands was 
34 
 
determined by ImageJ Software (116), normalized to actin, and then compared to average control 
values in each experiment. 
 
II. Analyses of Sputum from Subjects with CF. 
Subject Demographics and Sputum Collection. Subjects were recruited from the VCU CF 
Center. The study was approved by the Institutional Review Board at VCU (HM12402); subjects 
or parents/guardians provided written informed consent before enrollment into the VCU 
Biospecimen Repository and for participation in the CF Foundation Registry. Fifteen subjects were 
selected for this retrospective study. Two sputum samples per subject, one collected during a 
hospitalization for a pulmonary exacerbation and a second sample collected during an outpatient 
visit within six months of that hospitalization, were analyzed. All subjects spontaneously 
expectorated sputum and had mild-to-moderate (FEV1 50-98% predicted) or severe (FEV1<50% 
predicted) obstructive lung disease. Inclusion criteria consisted of: age greater than or equal to 6 
years old, and positive sweat chloride test. Exclusion criteria included: inability to perform 
spirometry, inability to spontaneously expectorate sputum, current treatment with tricyclic 
antidepressants, which have been demonstrated to inhibit acid SMase activity (e.g. 
amitriptyline)(6), or lung transplantation. There were no further exclusion criteria concerning 
medication use or participation in other research studies. Subject demographics are detailed in 
Table 3. 
An aliquot of sputum was sent for bacteriology cultures, performed according to CF 
Foundation standard protocols at the beginning of therapy (114). Any remaining aliquots of 
sputum were visually separated from saliva and oral detritus, and stored for later analysis at -80°C. 
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Table 3. Subject demographics. 
Subject  Gender Age CF Genotype Clinical Status 
FEV1 
% 
predicted 
MRSA  P. aeruginosa 
1 M 21 
c.1022_1023insTC, 
c.1521_1523delCTT 
H 65 + - 
O 80 + - 
2 
M 25 
c.1521_1523delCTT, 
c.2825delT 
H 44 + - 
O 59 + - 
3 
F 19 
Unknown H 21 - + 
O 27 - + 
4 M 16 
c.1521_1523delCTT,  
c.1021T>C 
H 58 + - 
O 73 + - 
5 
M 17 
c.1521_1523delCTT,  
c.1680-1G>A 
H 28 - - 
O 33 - + 
6 
M 39 
c.1521_1523delCTT, 
c.1521_1523delCTT 
H 60 + - 
O 57 + - 
7 F 15 
c.1521_1523delCTT, 
c.1521_1523delCTT 
H 42 - + 
O 39 - + 
8 
F 19 
c.1521_1523delCTT,  
c.54-5940_273+10250del21kb 
H 33 - + 
O 28 - + 
9 M 37 
c.1521_1523delCTT, 
c.1521_1523delCTT 
H 41 - + 
O 48 - + 
10 M 20 
c.1521_1523delCTT, 
c.1521_1523delCTT 
H 42 - + 
O 49 + + 
11 F 13 
c.1521_1523delCTT, 
c.3909C>G 
H 50 + - 
O 59 + + 
12 F 16 
c.1521_1523delCTT,  
c.1397C>A 
H 26 - + 
O 27 - + 
13 
F 18 
c.1521_1523delCTT, 
c.1521_1523delCTT 
H 39 + - 
O 45 + - 
14 F 17 
c.1521_1523delCTT, 
c.1400T>C 
H 26 - + 
O 28 + + 
15 M 12 
c.1521_1523delCTT, 
c.1521_1523delCTT 
H 84 - - 
O 82 - - 
 
H, hospitalization; O, outpatient clinic visit; M, male; F, Female; +, positive culture; -, negative 
culture. 
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Sputum Processing. Frozen sputum samples were thawed on ice. Afterwards, samples 
were weighed, and mixed with an equal volume (1:1, weight (mg):volume (mL)) of normal saline 
with 10% Sputolysin (0.1% DTT; Calbiochem/EMD Millipore, Billerica, MA). Diluted sputum 
samples were mixed by vortexing at room temperature for 15-30 sec. Next, samples were 
incubated at 37°C for 15 min. After mixing samples gently by inversion, they were centrifuged at 
25000×g for 30 min at 4°C to collect the sputum supernatant which was immediately aliquoted 
and either used for measuring NE activity or sent for sphingolipid analysis. 
Neutrophil Elastase Activity Assay. NE activity in sputum supernatants was measured 
using a chromogenic microtiter plate assay with Succinyl-Ala-Ala-Pro-Val-p-nitroanalide (3mM, 
in 50% DMSO; Sigma-Aldrich, St. Louis, MO) as the substrate, as detailed previously (39, 146). 
In summation, NE standards, using human sputum-derived active NE (SE563, Elastin Products, 
Owensville, MI), were made at concentrations of: 30, 15, 7.5, 3.75, 1.875, 0.94, 0.47, 0.23 and 0 
µg/mL in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Buffer (0.125M HEPES, 
pH 7.5, 0.125% Triton-X 100). A volume of 100µL of standard or sample was mixed with 100µL 
of saline in the wells of a 96-well plate, and 50µL of substrate were added to each well. Absorbance 
at λ=405nm was read with a spectrophotometer for 3 min. NE activity (µg/mL) was plotted against 
the slope of the increase of absorbance (OD/min). The concentration of active NE was expressed 
in nM, extrapolated from the standard curve (30, 15, 7.5, 3.75, 1.875, 0.94, 0.47, 0.23 and 0 
µg/mL). 
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III. Sphingolipid Analysis.  
Both BAL fluid (350µL) and sputum supernatants were assessed for sphingolipid content 
by the Lipidomics/Metabolomics Core at VCU, using reverse phase high-performance liquid 
chromatography/electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) (119, 
151). In summary, samples were processed to extract lipids as follows. After transferring samples 
into borosilicate tubes with a Teflon-lined cap (#60827-453, VWR, West Chester, PA), 2mL of 
CH3OH, 1mL of CHCl3 and the internal standard cocktail (250pmol of each sphingolipid species, 
dissolved in a final total volume of 10µl of 7:2:1 ethanol:methanol:water) were added.  Contents 
were dispersed by applying an ultra sonicator (30sec, at room temperature), and the resulting 
single-phase mixture incubated at 48°C overnight. Samples were cooled, and 150µl of 1M KOH 
in CH3OH added. After sonication, samples were incubated in a shaking water bath ( 37°C, 2h). 
Glacial acetic acid (12µl) was added to bring the extract to neutral pH. Samples were centrifuged, 
the supernatant transferred to a new tube, and dried using a Speed Vac. Dried sample residue was 
reconstituted in 0.5 mL of the starting mobile phase solvent for LC-MS/MS analysis and sonicated 
briefly for 15sec. After centrifugation for 5min in a tabletop centrifuge, supernatant was transferred 
to autoinjector vials for analysis. Sphingolipids were separated by reverse phase liquid 
chromatography using a Supelco 2.1 (i.d.) × 50 mm Ascentis Express C18 column (Sigma, St. 
Louis, MO) and binary solvent system (flow rate, 0.5 mL/min) with the column oven set to a 
temperature of 35°C. 
Samples separated by reverse phase chromatography were nebulized, charged using an 
electrospray ionization source, and resolved in an AB Sciex 5500 quadrupole/linear ion trap 
(QTrap) (SCIEX Framingham, MA) operating in a triple quadrupole mode. Q1 and Q3 were set to 
pass molecularly distinctive precursor and product ions (or a scan across multiple m/z in Q1 or 
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Q3), using N2 to collisionally induce dissociations in Q2 (which was offset from Q1 by 30-120 
eV); the ion source temperature was set to 500°C. 
Samples were assayed for the following sphingolipids: sphingosine, sphinganine, S1P, 
sphinganine-1-phosphate (Sa1P), as well as sphingomyelin, ceramide, monohexosylceramide 
moieties with the following fatty acid chain lengths— d18:1/14:0, d18:1/16:0, d18:1/18:1, d18:1/18:0, d18:1/22:0, 
d18:1/24:1, d18:1/24:0, d18:1/26:1, and d18:1/26:0. For sphingolipid nomenclature (for example, d18:1/14:0), the 
first number describes the sphingoid base (18:1 represents sphingosine) and the second the fatty 
acid chain (14:0 for a 14-carbon chain). 
 
IV. Statistical Analyses. 
Mouse Data. Quantitation of sphingolipids— ceramide, monohexosylceramides, 
sphingosine, sphinganine, S1P, Sa1P, and sphingomyelin in BAL, BAL total cell numbers 
differentials, BAL cytokine levels, as well as relative mRNA and protein expression were 
compared among the treatment groups using either Mann-Whitney U Tests (Wilcoxon Rank Sum 
Test), or, if there were more than two conditions, using one-way nonparametric ANOVA analyses 
(Kruskal-Wallis Test) with post hoc multiple comparison adjustments using Mann-Whitney U 
Tests (Wilcoxon Rank Sum Test) (GraphPad Prism, La Jolla, CA ). Data are presented as mean ± 
SEM, with differences of p<0.05 considered statistically significant. 
Human Data. For human samples, we used a two-tailed, nonparametric paired statistical 
test: the Wilcoxon Signed Rank Test, to determine whether there were significant differences 
between stable and exacerbated sputum measures for sphingolipid levels, and for the concentration 
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of active NE, and FEV1 % predicted using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, 
CA)(153). Differences between groups were considered significant at p<0.05. We used linear 
correlation to determine the association between concentrations of active NE and sphingolipid 
levels using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). Again, p-value of less 
than 0.05 was considered statistically significant. 
Data were also analyzed using a linear mixed model (148), to determine the likelihood of 
an association between the concentration of NE and various sphingolipids, as well as whether (i) 
bacterial culture positive for methicillin resistant Staphylococcus aureus (MRSA) or Pseudomonas 
aeruginosa, (ii) patient lung function, or (iii) patient sex, modified the association. A p-value less 
than 0.05 was considered statistically significant. 
 
 
 
 
 
 
Chapter 3: Results 
 
 
 
 
I. Neutrophil Elastase Induced Changes in Sphingolipid Levels in Mouse Airways. 
Oropharyngeal Aspiration of Neutrophil Elastase Increased the Levels of Ceramide in 
Murine Airways. Previously, it has been shown that oropharyngeal aspiration of NE causes airway 
inflammation in mice (47, 143); we used this model to determine whether NE-induced 
inflammation correlated with increased airway sphingolipids. As detailed previously (47, 143) and 
in the Methods section, mice were administered three doses of NE or vehicle control on days 1, 4, 
and 7 (Figure 3). At 4h (n=4 animals per group), 8h (n=4 animals per group), or 24h (n=14 control, 
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n=16 NE) after the final dose of NE was administered, mice were euthanized, and BAL and tissue 
samples collected for analysis. In order to characterize the sphingolipid profile associated with 
airway inflammation in this model, sphingolipid concentrations in BAL were determined by 
HPLC-ESI-MS/MS (Tables 4-7). 
First, we assessed BAL for the presence of sphingomyelin, ceramide, and 
monohexosylceramide moieties (d18:1/14:0, d18:1/16:0, d18:1/18:1, d18:1/18:0, d18:1/22:0, d18:1/24:1, d18:1/24:0, 
d18:1/26:1, and d18:1/26:0) as well as sphingosine, sphinganine, S1P and Sa1P. Levels of these 
sphingolipids after aspiration of NE were compared with controls at the same time point— 4, 8, 
or 24h after the third and final NE dose was administered. To track overarching trends in 
sphingolipid levels, we calculated the sum of sphingomyelin, ceramide, and 
monohexosylceramide moieties, reported as total sphingomyelin (Table 4), total ceramide (Table 
5), and total monohexosylceramide (Table 6), respectively, and depicted in Figure 4. At 24h, we 
observed that mice administered NE demonstrated a 2.5-fold increase in total ceramide, a 
statistically significant difference (p<0.001) from the levels observed in control treated animals 
(Table 5, Figure 4). However, the levels of total sphingomyelin (Table 4) and 
monohexosylceramide (Table 6), and likewise levels of sphingosine, sphinganine, S1P and Sa1P 
(Table 7) did not differ significantly between control and NE groups at 24h. Analyzing the 
different ceramide moieties present in BAL revealed that total ceramide was increased due to 
statistically significant increases in long chain ceramides. Specifically, levels of d18:1/22:0, d18:1/24:0 
and d18:1/24:1 ceramide moieties increased by approximately 145% (p= 0.003), 211% (p=0.001), 
and 256%, (p=0.001), respectively (Table 5, Figure 5). There was also a statistically significant 
increase in d18:1/26:0 ceramide (Table 5), but the levels of the moiety present in murine BAL— 
below 10 pmol/mL— led us to conclude the effects of this ceramide were likely negligible. 
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Analyzing individual sphingomyelin and monohexosylceramide moieties revealed no further 
statistically significant differences in sphingolipid levels between control and NE groups at 24h 
(Table 4, 6). However, there were trends towards increased d18:1/22:0, d18:1/24:1, d18:1/24:0 
sphingomyelin moieties at 4 and 8h after NE was administered compared to controls. Similarly, 
there were no significant variations in sphingolipid levels between animals that were administered 
vehicle control versus NE at either 4 or 8h when the total sphingolipids or individual moieties were 
analyzed (Tables 4-7). 
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Table 4. Levels of sphingomyelin moieties in BAL in mice administered vehicle control or NE. 
 4ha 8hb 24hc 
Sphingomyelin 
(pmol/ml) 
Control NE Control NE Control NE 
d18:1/14:0 18.48±0.89 23.25±2.42 26.03±6.25 23.9±3.21 17.70±0.68 27.68±3.48 
d18:1/16:0 584.53±13.68 676.33±32.12 641.73±31.68 735.20±20.40 1196.73±103.19 1371.26±154.38 
d18:1/18:1 48.20±0.94 51.68±4.40 52.23±4.74 56.20±1.66 1630.47±252.92 2232.50±475.68 
d18:1/18:0 527.83±12.34 609.70±26.59 520.20±63.91 625.70±9.29 2073.24±274.02 2075.27±284.77 
d18:1/20:0 1243.18±11.63 1260.18±46.95 1280.58±80.29 1322.23±70.25 2867.21±265.25 2936.53±300.19 
d18:1/22:0 378.65±12.60 536.75±27.06 374.58±44.72 555.47±79.14 258.48±20.90 414.88±40.11 
d18:1/24:1 260.63±4.17 383.43±24.19 296.33±25.99 424.03±56.12 232.93±13.63 514.47±58.21 
d18:1/24:0 182.23±6.14 247.95±16.21 206.85±28.06 293.30±47.27 138.83±11.04 282.31±29.03 
d18:1/26:1 14.63±0.43 16.68±1.77 17.35±3.26 19.37±2.72 6.86±1.19 11.31±1.66 
d18:1/26:0 18.63±0.92 19.03±1.76 21.35±3.89 22.57±2.59 7.99±1.57 12.74±2.20 
Totald 3276.97±39.07 3824.96±168.32 3437.27±195.57 4077.94±189.75 10470.43±1154.85 11669.64±1437.65 
 
a BAL collected at 4h (n=4 per group). b BAL collected at 8h (n=4 control, 3 NE, respectively). c BAL collected at 24 h (n=16 control, 
n=14 NE). d Total sphingomyelin represents the mean of a summation of individual sphingomyelin moieties at each time point; total 
sphingomyelin at 24 h is also shown in Figure 2. Samples were collected and processed using LC-MS/MS. Data are expressed as mean 
± SEM pmol/mL BAL fluid, with comparisons between control and NE treated groups at each time point. There are no statistically 
significant differences in sphingolipid profile at each time point.  
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Table 5. Levels of ceramide moieties in BAL in mice administered vehicle control or NE. 
 4ha 8hb 24hc 
Ceramide 
(pmol/ml) 
Control NE Control NE Control NE 
d18:1/14:0 0.20± 0.02 0.13±0.02 0.24±0.07 0.14±0.01 5.83±1.35 3.43±0.88 
d18:1/16:0 245.02±28.27 120.47±13.9 236.23±31.64 124.73±4.25 89.31±16.33 110.17±15.30 
d18:1/18:1 5.14±0.33 3.15±0.15 5.31±0.37 5.00±1.00 17.01±2.79 21.33±4.87 
d18:1/18:0 3.14±0.64 1.92±0.08 2.14±0.23 3.40±1.65 8.96±1.36 10.18±1.96 
d18:1/20:0 4.99±0.30 3.25±0.54 4.97±0.70 6.34±3.28 8.41±1.03 13.34±2.23 
d18:1/22:0 22.72±2.70 19.01±1.84 22.96±3.15 25.38±5.56 29.23±4.85 63.81±10.89* 
d18:1/24:1 85.41±3.39 46.86±3.51 69.74±7.90 79.41±21.95 76.91±9.26 227.03±38.19* 
d18:1/24:0 91.54±19.27 67.93±10.44 104.52±5.79 101.96±19.20 98.85±10.66 268.46±41.43* 
d18:1/26:1 6.32±0.15 4.03±0.25 7.12±0.60 5.91±0.79 8.70±1.04 8.79±1.73 
d18:1/26:0 5.03±0.10 3.25±0.23 5.79±0.55 4.72±0.67 3.79±0.72 7.05±0.62* 
Totald 469.52±40.10 270.01±16.92 459.04±39.52 357.00±55.31 349.34±32.57 738.52±96.90* 
 
a BAL collected at 4h (n=4 per group). b BAL collected at 8h (n=4 control, 3 NE, respectively). c BAL collected at 24 h (n=16 control, 
n=14 NE). d Total ceramide represents the mean of a summation of individual ceramide moieties at each time point; total ceramide at 
24 h is also shown in Figure 2. Samples were collected and processed using LC-MS/MS. Data are expressed as mean ± SEM pmol/mL 
BAL fluid, with comparisons between control and NE treated groups at each time point. *, p<0.05, when compared to control animals 
at the same time point. Ceramide moieties d18:1/22:0, d18:1/24:1, and d18:1/24:0 at 24 h are also displayed in Figure 3.  
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Table 6. Levels of monohexosylceramide moieties in BAL in mice administered vehicle control or NE. 
 4ha 8hb 24hc 
Monohexosylceramide 
(pmol/ml) 
Control NE Control NE Control NE 
d18:1/14:0 1.24±0.17 1.61±0.20 1.17±0.19 1.60±0.21 1.92±0.44 2.35±0.46 
d18:1/16:0 20.35±1.95 14.02±0.80 20.20±1.33 20.25±2.85 39.83±7.22 28.40±4.08 
d18:1/18:1 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.10±0.02 0.18±0.06 
d18:1/18:0 0.14±0.04 0.33±0.08 0.03±0.02 0.12±0.09 0.41±0.11 0.43±0.09 
d18:1/20:0 0.98±0.15 1.21±0.25 0.74±0.14 0.95±0.03 0.63±0.12 0.71±0.17 
d18:1/22:0 12.40±1.23 12.70±2.03 13.51±3.45 13.24±2.61 12.23±2.70 7.97±2.28 
d18:1/24:1 22.28±4.38 22.49±2.09 30.93±5.01 31.41±3.23 12.30±3.61 12.17±7.31 
d18:1/24:0 55.70±2.70 69.15±7.77 64.75±5.45 80.42±11.69 22.99±6.19 22.31±11.11 
d18:1/26:1 4.89±0.21 5.22±0.75 5.11±0.21 7.45±1.77 2.18±0.58 0.74±0.39 
d18:1/26:0 1.23±0.25 1.14±0.09 1.01±0.10 1.51±0.32 0.44±0.20 1.00±0.31 
Totald 119.20±8.51 127.88±12.69 137.46±13.58 156.94±17.84 144.71±20.21 193.79±26.34 
 
a BAL collected at 4h (n=4 per group). b BAL collected at 8h (n=4 control, 3 NE, respectively). c BAL collected at 24 h (n=16 control, 
n=14 NE). d Total monohexosylceramide represents the mean of a summation of individual monohexosylceramide moieties at each time 
point; total monohexosylceramide at 24 h is also shown in Figure 2. Samples were collected and processed using LC-MS/MS. Data are 
expressed as mean ± SEM pmol/mL BAL fluid, with comparisons between control and NE treated groups at each time point. There are 
no statistically significant differences in sphingolipid profile at each time point   
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Table 7. Levels of sphingosine, S1P, sphinganine, and Sa1P in BAL in mice administered vehicle control or NE. 
 4ha 8hb 24hc 
Sphingolipid 
(pmol/ml) 
Control NE Control NE Control NE 
sphingosine 15.00±1.21 26.04±0.96 20.12±1.33 23.12±3.33 70.83±24.31 64.18±28.68 
S1P 5.34±0.19 6.50±0.42 7.85±1.03 8.20±1.03 4.58±0.90 9.90±3.83 
sphinganine 1.97±0.30 1.86±0.25 1.88±0.37 3.17±1.03 2.64±0.53 7.90±3.38 
Sa1P 0.50±0.02 0.56±0.03 0.44±0.07 0.43±0.03 1.59±0.40 3.11±1.25 
 
a BAL collected at 4h (n=4 per group). b BAL collected at 8h (n=4 control, 3 NE, respectively). c BAL collected at 24 h (n=16 control, 
n=14 NE). Samples were collected and processed using LC-MS/MS. Data are expressed as mean ± SEM pmol/mL BAL fluid, with 
comparisons between control and NE treated groups at each time point. Sphingosine levels in BAL as 24 h — as sphingosine is the 
sphingoid base component within the sphingolipid moieties assessed— are also shown in Figure 2 as total sphingosine. There are no 
statistically significant differences in sphingolipid profile at each time point. 
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Figure 4. Total sphingolipid analysis of BAL from mice treated with control vehicle or NE. 
Mice were treated with NE (50µg; 42µM) or control vehicle by oropharyngeal aspiration on days 
1, 4, and 7. BAL (1mL) was harvested on day 8. The levels of total sphingomyelin (A), ceramide 
(B), sphingosine (C) and monohexosylceramide (D) in 350µL of murine BAL, measured by 
HPLC-ESI-MS/MS, were increased at 24h (day 8) after final NE administration compared to 
vehicle control. The data show sphingolipid content of BAL in pmol/mL, summarizing 2 
experiments, n=16 control, n=14 NE. Data (mean ± SEM) were compared by Mann-Whitney U 
(Wilcoxon Rank Sum) Test; ***, p<0.001. These data have been published (59). 
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Figure 5. Analysis of ceramide chain length in BAL of mice treated with control vehicle or 
NE. Mice were treated with NE (50µg, 42µM) or control vehicle on days 1, 4, and 7. BAL (1mL) 
was harvested on day 8. The ceramide levels in murine BAL (350µL) were measured by HPLC-
ESI-MS/MS at 24h after final NE administration compared to vehicle control. Ceramide d18:1/22:0 
(A), d18:1/24:1 (B), d18:1/24:0 (C) moieties were increased. The data show sphingolipid content of BAL 
in pmol/mL, summarizing 2 experiments, n=16 control, n=14 NE. Data are summarized as mean 
± SEM and compared by Mann-Whitney U (Wilcoxon Rank Sum) Test; **, p<0.01, ***, p<0.001. 
These data have been published (59). 
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Administering Neutrophil Elastase Increased the Concentration of SPTLC2 Protein in 
Murine Lungs. To determine how NE modulated ceramide levels, we investigated whether NE 
stimulated de novo ceramide synthesis by modulating SPT expression. We analyzed the protein 
expression levels of the two best-characterized subunits of SPT, the enzyme responsible for the 
rate-limiting step of de novo sphingolipid synthesis. At 4 and 8h, SPTLC2 protein expression did 
not differ between mice administered NE and those given vehicle control (Figure 6). In contrast, 
at 24h, the level of SPTLC2 protein in whole lung lysates was increased in NE-treated animals by 
approximately 2.5-fold (p<0.001) (Figure 7). The levels of SPTLC1 protein were decreased, 
dropping by approximately 30% (p=0.019) compared to control treated mice at the same time point 
(Figure 7).  
To determine whether the observed changes in SPT subunits’ protein concentration 
reflected a change in transcription, we assessed the levels of SPTLC1 and SPTLC2 mRNA in 
mouse lungs using Q/RT-PCR. Interestingly, there were no significant changes in SPTLC1 or 
SPTLC2 mRNA levels detectable in mouse lungs at 4, 8, or 24h following the final NE exposure, 
compared to vehicle controls (Figure 8). 
There are two known modulators of SPT activity— ORMDL3 and RTN4 (15, 16), but their 
effect on the expression of SPT are unknown. Since an increase in SPT expression could be 
accompanied by a change in the levels of ORMDL3 or RTN4, we investigated the expression of 
these proteins in mouse whole lung lysates. Protein expression of ORMDL3 and RTN4 was 
unchanged in NE-treated mice compared to controls at 24h (p=0.068 and p=0.579, respectively) 
(Figure 9), although there was a trend towards increased levels of ORMDL3 in NE-treated 
animals. Thus, currently, we have no evidence to support a role for ORMDL3 or RTN4 to regulate 
SPT activity or expression in this mouse model. Therefore, the increase in d18:1/22:0, d18:1/24:0 and 
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d18:1/24:1 ceramide (Table 5, Figure 5) was likely due to increased SPT enzymatic activity due to 
increased expression of SPTLC2. 
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Figure 6. Oropharyngeal aspiration of NE did not alter the level of SPTLC2 in murine lungs 
at 4 or 8h. Representative western blots of SPT long chain subunit 2 in mouse lung lysates at 4h 
(A) and 8h (B) after the final oropharyngeal aspiration of vehicle control or NE. In the top panel, 
representative westerns for SPTLC2 and actin are shown. In the bottom panel, the relative 
densitometries of bands are presented following normalization to actin and average control, 
expressed as percent of control. Data are presented as mean ± SEM, summarized from 1 
experiment (4h, 8h, n=4 mice per group) and compared by Mann-Whitney U (Wilcoxon Rank 
Sum) Test; ***, p<0.001. 
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Figure 7. Oropharyngeal aspiration of NE altered expression of SPTLC1 and SPTLC2 in 
mouse lungs. Representative western blots of SPT long chain subunits 1 and 2 in mouse lung 
lysates at 24h after administration of NE or control vehicle, probed for SPTLC1 (A, B), or SPTLC2 
(C, D) after the final oropharyngeal aspiration of vehicle control or NE. In the top panel (A, C), 
representative westerns for SPTLC1 or SPTLC2 and actin are shown. In the bottom panel (B, D), 
the relative densitometries of bands are presented following normalization to actin, shown as 
percentage of average control. Data are expressed as mean ± SEM; summarized from 2 
experiments, n=10 mice per group, and compared by Mann-Whitney U (Wilcoxon Rank Sum) 
Test; ***, p<0.001; *, p<0.05. These data have been published (59). 
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Figure 8. Q/RT-PCR analysis of SPTLC1 and SPTLC2 expression in the lungs of mice at 4, 
8, and 24 h after exposure to control vehicle or NE. Relative expression of SPTLC1 (A) and 
SPTLC2 (B) mRNA in mouse lung lysates at 4, 8, or 24h after the final oropharyngeal aspiration 
of vehicle control or NE. RNA was isolated from frozen murine lungs using QIAzol, a Trizol 
reagent, and the levels of target mRNA expression determined using Q/RT-PCR. SPTLC1 and 
SPTLC2 were normalized to β-actin, the endogenous control, and expressed relative to controls at 
the same time point using the ΔΔCt method. Data are summarized from 1 (4h, 8h) or 3 (24h) 
experiments, n=4 per group (4h, 8h) or n=11 or 12 (24h, control, SPTLC1 and SPTLC2, 
respectively), n=15 (24h NE). Data are expressed as mean ± SEM and compared by Mann-
Whitney U (Wilcoxon Rank Sum) Test; p>0.05.  
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Figure 9. Oropharyngeal aspiration of NE did not alter the concentration of RTN4 or 
ORMDL3 in murine lungs at 24h. Representative western blots of RTN4 and ORMDL3 in 
mouse lung lysates at 24h after the final oropharyngeal aspiration of vehicle control or NE (A). 
The relative densitometries of bands are presented following normalization to actin and shown as 
percent of average control, with relative densitometry for RTN4 depicted in panel in (B) and 
ORMDL3 in (C). Data are expressed as mean ± SEM; summarized from 2 experiments (n=10 
mice per group) and compared by Mann-Whitney U (Wilcoxon Rank Sum) Test. 
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II. Inhibiting SPT Activity Decreased Ceramide Expression and Airway Inflammation. 
Inhibiting SPT Activity Decreased Neutrophil Elastase-induced Ceramide Expression. 
To verify that increased ceramide in the BAL from mice administered NE was due to an increase 
in de novo biosynthesis of ceramide, we pre-treated mice with intraperitoneal injections of 
myriocin or vehicle control on days 1, 4, and 7 and euthanized mice at day 8, 24h after final 
administration of NE. Myriocin is a fungus-derived inhibitor that forms covalent bonds at the 
active site of SPT and irreversibly inhibits enzyme activity (147). In order to characterize the 
sphingolipid profile associated with pre-treatment with myriocin prior to induction of airway 
inflammation in this model, sphingolipid concentrations in BAL were determined via HPLC-ESI-
MS/MS (Tables 8-11). The variability among the three experiments in murine response to NE, 
warranted analysis of the data as percent of control (% of control), with sphingolipid profile in 
control animals as 100% for each of the three experiments.  
Administering myriocin to mice abrogated NE-induced changes in the expression of 
d18:1/22:0 (p=0.005) and d18:1/24:1 (p=0.011) ceramide; both ceramide moieties decreased by 
approximately 34% compared to levels in BAL in mice pre-treated with a vehicle control before 
NE was administered (Table 9, Figure 10). Similarly, there was a downward trend in the levels 
of d18:1/24:0 ceramide, which decreased by about 27% (p= 0.077). Thus, we observed a downward 
trend in the levels of total ceramide, which dropped by approximately 18% in mice pre-treated 
with myriocin in comparison to vehicle control prior to oropharyngeal aspiration of NE, but not a 
statistically significant difference (p= 0.111) (Table 9, Figure 10). Pre-treatment with myriocin 
also decreased levels of d18:1/26:1 and d18:1/26:0 ceramide (Table 9). However, as in prior 
experiments, the levels of the moiety present in murine BAL— below 15pmol/mL— led us to 
conclude the effects of these two ceramide moieties were likely negligible.  
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Pre-treatment with myriocin also decreased levels of d18:1/14:0 sphingomyelin by about 24% 
compared to animals pre-treated with vehicle control (Table 8); however, as the levels of this 
sphingomyelin moiety was not increased by NE compared to controls, we did not pursue this 
further. Similarly, we observed an increase in d18:1/22:0, d18:1/24:1, d18:1/24:0, and d18:1/26:1 
sphingomyelin (Table 8) and d18:1/24:1 and d18:1/26:1 monohexosylceramide (Table 10) in mice 
administered NE compared to vehicle control. There were no statistically different alterations in 
these sphingolipids in mice pre-treated with myriocin prior to NE, compared to those pre-treated 
with vehicle control before NE, so we did not pursue these trends further. 
Interestingly, pre-treatment with myriocin did not significantly affect the levels of 
monohexosylceramide (Table 10), sphingosine, sphinganine, S1P, or Sa1P (Table 11). Likewise, 
myriocin did not alter the expression of SPTLC2 protein in mouse lung lysates (Figure 11). Thus, 
ceramides generated via the de novo pathway significantly contributed to the increased ceramide 
levels observed in BAL after NE exposure. 
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Table 8. Levels of sphingomyelin moieties in BAL in mice administered myriocin prior to aspiration of vehicle control or NE. 
Sphingomyelina 
(% of control) 
Control NE Myriocin NE + Myriocin 
d18:1/14:0 100.01±3.17 100.53±6.99 77.72±6.34 76.71±5.29+ 
d18:1/16:0 93.58±3.61 106.62±7.19 84.74±3.07 101.51±5.10 
d18:1/18:1 100.00±4.08 148.30±16.41 87.49±4.79 147.22±21.84 
d18:1/18:0 100.00±3.43 106.76±6.09 82.80±3.86 98.10±5.69 
d18:1/20:0 100.00±5.06 93.36±5.57 90.58±3.95 96.10±7.70 
d18:1/22:0 100.00±2.56 184.78±16.03* 98.10±6.43 143.28±20.49 
d18:1/24:1 100.00±3.03 144.51±8.83* 90.14±5.28 137.51±14.46 
d18:1/24:0 100.00±3.42 159.94±10.89* 93.07±7.35 140.01±16.38 
d18:1/26:1 100.02±4.56 149.89±9.24* 93.70±3.85 1400.76±14.56 
d18:1/26:0 99.99±5.01 129.02±10.39 92.68±5.59 135.58±16.98 
Total 100.00±2.88 128.68±7.65 90.86±4.21 122.89±11.87 
 
a BAL collected from n= 15 per group, except NE+myriocin where n=14. Samples were collected and processed using LC-MS/MS. 
Data are expressed as mean ± SEM, after normalizing to average control within each experiment. *, p<0.05, when compared to control 
animals at the same time point; +, p<0.05, when compared to NE-treated animals at the same time point. 
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Table 9. Levels of ceramide moieties in BAL in mice administered myriocin prior to aspiration of vehicle control or NE. 
Ceramidea 
(% of control) 
Control NE Myriocin NE + Myriocin 
d18:1/14:0 100.16±5.43 95.67±14.33 102.09±10.73 82.08±4.55 
d18:1/16:0 99.99±5.89 99.82±10.15 78.83±6.62 89.57±7.77 
d18:1/18:1 103.44±15.30 147.83±12.86 119.63±13.19 128.52±22.35 
d18:1/18:0 100.01±7.58 115.39±16.09 107.43±16.58 109.32±14.63 
d18:1/20:0 100.00±7.78 116.87±11.56 95.46±11.36 94.33±6.27 
d18:1/22:0 100.00±5.17 175.75±13.24* 100.89±12.21 123.67±7.21+ 
d18:1/24:1 100.00±5.56 204.20±16.47* 92.53±7.83 151.21±9.92+ 
d18:1/24:0 100.00±5.89 178.95±15.07* 85.65±5.85 139.27±9.02 
d18:1/26:1 100.03±4.03 212.57±20.81* 82.25±6.54 162.20±15.59 
d18:1/26:0 100.00±4.95 198.52±19.91* 84.57±5.15 159.05±15.08 
Total 100.00±5.03 150.65±11.00 * 85.98±6.48 123.33±8.52 
 
a BAL collected from n= 15 per group, except NE+myriocin where n=14. Samples were collected and processed using LC-MS/MS. 
Data are expressed as mean ± SEM, after normalizing to average control within each experiment. *, p<0.05, when compared to control 
animals at the same time point; +, p<0.05, when compared to NE-treated animals at the same time point. 
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Table 10. Levels of monohexosylceramide moieties in BAL in mice administered myriocin prior to aspiration of vehicle control 
or NE. 
Monohexosylceramidea 
(% of control) 
Control NE Myriocin NE + Myriocin 
d18:1/14:0 100.27±7.87 91.55±5.55 91.12±8.53 99.97±12.29 
d18:1/16:0 100.01±8.53 98.89±8.00 91.85±10.25 83.63±9.04 
d18:1/18:1 58.49±12.65 89.63±24.80 110.18±42.43 118.10±31.99 
d18:1/18:0 100.21±6.31 309.59±105.34 161.88±31.17 178.23±81.15 
d18:1/20:0 99.95±6.82 128.19±19.20 105.53±10.84 100.56±8.11 
d18:1/22:0 100.04±7.42 133.77±10.96 107.57±12.50 115.10±7.11 
d18:1/24:1 100.00±7.77 148.05±13.13* 112.96±15.25 144.02±13.85 
d18:1/24:0 100.00±5.69 127.44±10.42 96.44±10.00 113.80±11.24 
d18:1/26:1 100.07±5.29 152.11±15.73* 114.57±15.06 148.86±9.58 
d18:1/26:0 99.98±5.67 211.06±32.05 106.78±13.27 148.57±18.22 
Total 100.00±5.93 128.20±9.74 100.96±10.66 115.86±10.20 
 
a BAL collected from n= 15 per group, except NE+myriocin where n=14. Samples were collected and processed using LC-MS/MS. 
Data are expressed as mean ± SEM, after normalizing to average control within each experiment. *, p<0.05, when compared to control 
animals at the same time point. 
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Table 11. Levels of sphingosine, S1P, sphinganine, and Sa1P in BAL in mice administered myriocin prior to aspirating vehicle 
control or NE. 
Sphingolipida  
(% of control) 
Control NE Myriocin NE + Myriocin 
sphingosine 100.09±6.86 123.91±9.89 94.64±7.55 137.98±14.29 
S1P 99.39±7.97 132.09±10.89 94.09±9.48 143.70±12.58 
sphinganine 100.74±5.94 113.81±9.34 109.71±7.97 108.58±7.97 
Sa1P 106.69±14.93 136.94±24.33 94.61±13.54 151.32±24.31 
 
a BAL collected from n= 15 per group, except NE+myriocin where n=14. Samples were collected and processed using LC-MS/MS. 
Data are expressed as mean ± SEM, after normalizing to average control within each experiment. There are no statistically significant 
differences in sphingolipid profile among these four groups. 
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Figure 10. BAL sphingolipid analysis following myriocin pretreatment followed by NE or 
control vehicle. Mice were exposed to control vehicle or myriocin (0.3 mg/kg IP) 2h prior to NE 
or control vehicle on days 1, 4, and 7; BAL and mouse lungs were harvested on day 8. Sphingolipid 
concentration in BAL (350µL) was determined by HPLC-ESI-MS/MS. Expression of total 
ceramides (A) and ceramide d18:1/22:0 (B), d18:1/24:1 (C), d18:1/24:0 (D) in BAL were increased 
following NE exposure. With the addition of myriocin, a significant decrease in d18:1/22:0 and 
d18:1/24:1 ceramide was observed, with non-significant decreases for the d18:1/24:0 chain length and 
total ceramide. Data were normalized to the average control and compared using nonparametric 
one-way ANOVA (Kruskal-Wallis Test), with post hoc analyses among treatment groups using 
Mann-Whitney U (Wilcoxon Rank Sum Test). Data represent the sum of 3 experiments expressed 
as mean ± SEM, with n=15 animals per group except NE+myriocin (n=14). ***, p<0.001; **, 
p<0.01; *, p<0.05; n.s., not significant, p>0.05. These data have been published (59). 
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Figure 11. Oropharyngeal aspiration of NE increased the concentration of SPTLC2 in 
murine lungs at 24h; pre-treatment with myriocin did not abrogate this effect. Mice were 
administered myriocin (0.3 mg/kg IP) or vehicle control on days 1, 4, and 4 prior to oropharyngeal 
aspiration of NE or vehicle control; BAL and mouse lungs were harvested on day 8. Representative 
western blots of SPT long chain subunit 2 in mouse lung lysates at 24h (A) after the final 
oropharyngeal aspiration of vehicle control or NE. In the top panel, representative westerns for 
SPTLC2 and actin are shown. In the bottom panel, the relative densitometries of bands are 
presented following normalization to actin and average control, expressed as percent of control. 
Data are presented as mean ± SEM, summarized from 2 experiments (n=8 mice per group) and 
compared by Mann-Whitney U (Wilcoxon Rank Sum) Test; *, p<0.05; n.s., not significant, 
p>0.05. 
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Myriocin Alleviated Aspects of Neutrophil Elastase-induced Inflammation. We 
measured the levels of inflammatory markers and quantity of inflammatory cells present in murine 
BAL in order to determine the effects of myriocin mediated inhibition of SPT activity on NE-
induced inflammation. Administering myriocin to mice prior to aspiration of NE induced a 36% 
decrease in the levels of KC (p=0.021) and 44% drop in the levels of HMGB1 (p=0.015) present 
in murine BAL (Figure 12). Pre-treatment with myriocin decreased the total leukocytes (total 
white blood cell count, total cell count) in mouse BAL by about 11% (Figure 13); a change that 
was not statistically significant. Likewise, while proportion of neutrophils present decreased by 
roughly 4% in the BAL of mice pre-treated with myriocin prior to oropharyngeal aspiration of NE 
(Figure 13), this drop was also not statistically significant. 
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Figure 12. The effect of myriocin on NE-induced KC and HMGB1 in BAL. Administration of 
myriocin (0.3 mg/kg) prior to oropharyngeal aspiration of NE decreased the level of BAL KC, 
compared to mice that received control vehicle prior to NE treatment, as determined by ELISA 
(n=13 per group in control, myriocin alone and NE+myriocin, n=14 in NE) (A). NE-induced 
expression of HMGB1 in BAL was decreased with myriocin administration (n=13 NE and n=12 
NE+myriocin) (B) a representative blot, and relative densitometry, normalized to HMGB1 
expression against average expression with NE (percentile). Data summarized mean ± SEM of 3 
experiments, with groups compared by Mann-Whitney U (Wilcoxon Rank Sum) Test; ***, 
p<0.001; +, p=0.021; *, p=0.014. These data have been published (59). 
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Figure 13. Total cell counts and percent neutrophils in BAL following pretreatment with 
myriocin or control vehicle and aspiration of NE or control vehicle. Aspiration of NE induced 
an increase in BAL total leukocytes (total cell count) (A), and in percent neutrophils (B). 
Administration of myriocin (0.3 mg/kg) by IP injection prior to NE administration did not change 
total cell count (total leukocytes) in murine BAL (A), or the percent neutrophils present in the 
BAL (B), compared to mice that received a vehicle control IP injection. Groups were compared 
by nonparametric ANOVA test (Kruskal-Wallis), with post-hoc comparisons among groups using 
Mann-Whitney U Tests (Wilcoxon Rank Sum Test); data are summarized from 3 experiments as 
mean ± SEM, with n= 15 per group (vehicle control, myriocin alone, NE alone), n=14 in 
NE+myriocin group; ***, p<0.001. These data have been published (59). 
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III. Associations between Sphingolipids, Neutrophil Elastase, and Clinical Status in Cystic 
Fibrosis Sputum. 
Sputum Sphingolipids Increased During Hospitalization. We evaluated the sphingolipid 
profiles of sputum from CF patients by comparing intrasubject levels between hospitalization and 
outpatient visit to determine if there were any trends associated with more airway inflammation 
(hospitalization) versus less inflammation (outpatient visit). Three sphingolipid moieties 
demonstrated a statistically significant increase when the subjects were hospitalized for pulmonary 
exacerbation: d18:1/14:0 ceramide by about 50% (p= 0.022), d18:1/24:1 ceramide by about 37% (p= 
0.041), and d18:1/24:0 monohexosylceramide by about 38% (p=0.026) (Figure 14C-E). As expected, 
lung function, measured as FEV1 % predicted, was significantly decreased during hospitalizations 
for pulmonary exacerbations compared to outpatient clinic visits (p=0.0182) (Figure 14A). There 
was a 5% difference between the average FEV1 % predicted during outpatient visits and during 
hospitalization (Figure 14A). On the other hand, the sputum concentrations of active NE collected 
during hospitalizations for CF pulmonary exacerbations were not significantly different from 
samples collected during outpatient visits (p=0.468) (Figure 14B). However, this lack of 
difference in level of active NE was likely because our sputum donors had relatively high levels 
of chronic neutrophilic inflammation, as most had severe lung disease. Similar findings have been 
reported by others (105). 
However, in contrast to the ceramide and monohexosylceramide species which increased 
for individuals during hospitalization (Figure 14C-E), there were no other intrasubject significant 
differences in sphingolipid levels between these two time points for other species: sphingomyelins 
(Figure 15), total ceramide and other ceramide species (Figure 16), monohexosylceramides 
(Figure 17), and sphingosine, sphinganine, S1P, and Sa1P (Figure 18). The lack of more 
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significant differences between hospitalization and outpatient visits may be due to the severity of 
lung disease in this patient population reflected by the high NE levels at both time points in many 
subjects. 
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Figure 14. Differences in lung function and sputum concentrations of active NE and 
sphingolipids in patients with CF between hospitalization and outpatient visit. Sputum 
samples were collected during the course of hospitalization or during an outpatient visit (n=15 per 
group) and processed as described in the Methods. Lung function, expressed as FEV1 % predicted, 
varied between the two groups; there was a statistically significant decrease in lung function during 
hospitalization for CF pulmonary exacerbation (A). Active NE was measured by a chromogenic 
microtiter plate assay; there was a wide range of NE activity among patients, but no statistically 
significant difference between the two sample groups (B). Sphingolipid content was measured by 
HPLC-ESI-MS/MS. Sputum concentrations of d18:1/14:0 ceramide (C), d18:1/24:1 ceramide (D) and 
d18:1/24:0 monohexosylceramide (E) varied with clinical status, with increased concentrations of 
these sphingolipids found in samples collected during hospitalization. The differences between the 
two groups were statistically significant (*, p<0.05). Data (mean ± SEM) were compared by 
Wilcoxon Signed Rank Tests. These data have been submitted for publication. 
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Figure 15. Sputum concentrations of sphingomyelin in patients during hospitalization for a 
pulmonary exacerbation and during an outpatient visit. Sputum samples were collected during 
hospitalization or during an outpatient visit (n=15 per group) and processed as described in the 
Methods. Sphingolipid content was measured by HPLC-ESI-MS/MS. Sputum concentrations of 
total sphingomyelin (A) and d18:1/14:0, d18:1/16:0, d18:1/18:0, d18:1/18:1, d18:1/20:0, d18:1/22:0, d18:1/24:0, 
d18:1/24:1, d18:1/26:0, d18:1/26:1 sphingomyelin moieties (B-K). The differences between the two groups 
were not statistically significant. Data (mean ± SEM) were compared by Wilcoxon Signed Rank 
Tests. These data have been submitted for publication.
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Figure 16. Sputum concentrations of ceramide in patients during hospitalization for a 
pulmonary exacerbation and during an outpatient visit. Sputum samples were collected during 
hospitalization or during an outpatient visit (n=15 per group) and processed as described in the 
Methods. Sphingolipid content was measured by HPLC-ESI-MS/MS. Sputum concentrations of 
total ceramide (A) and d18:1/16:0, d18:1/18:0, d18:1/18:1, d18:1/20:0, d18:1/22:0, d18:1/24:0, d18:1/26:0, d18:1/26:1 
ceramide moieties (B-I). The differences between the two groups were not statistically significant. 
Data (mean ± SEM) were compared by Wilcoxon Signed Rank Tests. These data have been 
submitted for publication. 
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Figure 17. Sputum concentrations of monohexosylceramide in patients during 
hospitalization for a pulmonary exacerbation and during an outpatient visit. Sputum samples 
were collected during the course of hospitalization or during an outpatient visit (n=15 per group) 
and processed as described in the Methods. Sphingolipid content was measured by HPLC-ESI-
MS/MS. Sputum concentrations of total monohexosylceramide (A) and d18:1/14:0, d18:1/16:0, d18:1/18:0, 
d18:1/18:1, d18:1/20:0, d18:1/22:0, d18:1/24:1, d18:1/26:0, d18:1/26:1 monohexosylceramide moieties (B-J). The 
differences between the two groups were not statistically significant. Data (mean ± SEM) were 
compared by Wilcoxon Signed Rank Tests. These data have been submitted for publication. 
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Figure 18. Sputum concentrations of sphingosine, sphinganine, S1P, and Sa1P in patients 
during hospitalization for a pulmonary exacerbation and during an outpatient visit. Sputum 
samples were collected during the course of hospitalization or during an outpatient visit (n=15 per 
group) and processed as described in the Methods. Sphingolipid content was measured by HPLC-
ESI-MS/MS. Sputum concentrations of sphingosine (A), sphinganine (B), S1P (C), Sa1P (D). The 
differences between the two groups were not statistically significant. Data (mean ± SEM) were 
compared by Wilcoxon Signed Rank tests. These data have been submitted for publication. 
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A Rise in Sphingolipid Concentration Correlated with Increasing Proteolytically Active 
NE in Sputum from Cystic Fibrosis Patients. Based on our in vivo experiments with 
oropharyngeal aspiration of NE, which revealed that NE increased long chain ceramide levels, we 
tested whether levels of sputum sphingolipids correlate with NE activity. We found that as the 
concentration of active NE in sputum increased, so did the concentration of a wide variety of 
sphingolipids. There were linear correlations between the concentrations of active NE and total 
sphingomyelin (r2=0.198; p=0.014), total ceramide (r2=0.152; p=0.033), total 
monohexosylceramide (r2=0.229; p=0.007), and S1P (r2=0.257; p=0.004) (Figure 19) in subject 
sputa. 
The concentrations of several different sphingomyelin moieties directly correlated with 
levels of active NE. There was a linear correlation between active NE and sphingomyelin d18:1/14:0 
(r2=0.364; p<0.001), d18:1/18:1 (r2=0.156; p=0.031), d18:1/22:0 (r2=0.293; p=0.002), d18:1/24:1 (r2=0.295; 
p=0.002), and d18:1/24:0 (r2=0.141; p=0.041) (Figure 20). When assessing the association of active 
NE and ceramide of various chain lengths, we observed a statistically significant linear correlation 
between active NE and ceramide d18:1/22:0 (r2=0.148; p=0.036) and d18:1/24:0 (r2=0.262; p=0.004) 
(Figure 21A-B). Finally, two specific monohexosylceramide moieties increased with increasing 
NE activity— d18:1/16:0 (r2=0.273; p=0.003) and d18:1/24:0 (r2=0.164; p=0.026) (Figure 21C-D). 
Overall, we observed that sputum concentrations of various sphingomyelin, ceramide and 
monohexosylceramide moieties directly correlated with sputum NE activity. 
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Figure 19. A linear correlation between the concentration of active NE and total 
sphingomyelin (A), total ceramide (B), total monohexosylceramide (C) and S1P (D) in CF 
sputum. Sputum samples were collected (n=30 samples, from 15 donors), and processed as 
described in the Methods. Total sphingolipid content was measured by HPLC-ESI-MS/MS, and 
the concentration of active NE in sputum was assessed using an NE activity assay. There was a 
linear correlation between the concentration of active NE and total sphingomyelin (r2=0.198; 
p=0.014), total ceramide (r2=0.152; p=0.033), total monohexosylceramide (r2=0.2293; p=0.007), 
and S1P (r2=0.257; p=0.004) in CF sputum (A through D, respectively). These data have been 
submitted for publication.  
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Figure 20. Linear correlations between the concentration of active NE and five 
sphingomyelin moieties in CF sputum. Sputum samples were collected (n=30 samples, from 15 
donors), and processed as described in the Methods. Sphingomyelin content was measured by 
HPLC-ESI-MS/MS, and the concentration of active NE in sputum was assessed using an NE 
activity assay. Most likely contributors to the observed increase in total sphingomyelin consisted 
of d18:1/14:0 (r2=0.364; p<0.001), d18:1/18:1 (r2=0.156; p=0.031), d18:1/22:0 (r2=0.293; p=0.002), d18:1/24:1 
(r2=0.2945; p=0.002), and d18:1/24:0 (r2=0.141; p=0.041) sphingomyelin (A through E, 
respectively). These data have been submitted for publication. 
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Figure 21. Linear correlations between the concentration of active NE and two ceramide and 
two monohexosylceramide moieties in CF sputum. Sputum samples were collected (n=30 
samples, from 15 donors), and processed as described in the Methods. Ceramide and 
monohexosylceramide content was measured by HPLC-ESI-MS/MS. The concentration of active 
NE in sputum was assessed using an NE activity assay. The sphingolipid moieties that likely 
contributed to the increase in total ceramide were d18:1/22:0 (r2=0.148; p=0.036) (A) and d18:1/24:0 
(r2=0.262; p=0.004) ceramide (B). The sphingolipid moieties that likely contributed to the increase 
in total monohexosylceramide were d18:1/16:0 (r2=0.273, p=0.003) (C) and d18:1/24:0 (r2=0.164, 
p=0.026) monohexosylceramide (D). These data have been submitted for publication. 
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IV. Modifying Factors That Alter Correlations between Sphingolipids and Neutrophil 
Elastase in Cystic Fibrosis Sputum. 
The presence of bacteria in sputum, severity of lung disease, and patient gender modified 
the association between active NE and certain sphingolipid moieties in CF sputum. In sputum 
samples that were culture positive for MRSA, there was a statistically significant, stronger 
association between active NE and d18:1/14:0 sphingomyelin (p=0.0034), d18:1/24:0 ceramide (p=0. 
0257), as well as total monohexosylceramide (p=0. 0064), due to changes in d18:1/14:0 and d18:1/16:0 
monohexosylceramide (p=0.0007and p=0.003, respectively) (Table 12). Surprisingly, the 
presence of P. aeruginosa in sputum did not significantly affect the associations between 
sphingolipids and active NE. FEV1 (% predicted) affected the association between d18:1/14:0 
sphingomyelin (p=0.0318) and active NE and d18:1/14:0 monohexosylceramide (p=0. 0403); the 
higher the lung function, the weaker the association between active NE and these two d18:1/14:0 
sphingolipid moieties (Table 12); the change was statistically significant. Finally, the subject’s 
gender significantly affected the association between d18:1/14:0 sphingomyelin (p=0.0015) and 
d18:1/14:0 monohexosylceramide (p=0.0472) and active NE. Females had a statistically significant, 
stronger association between those two sphingolipid moieties and active NE (Table 12). 
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Table 12. Modifying factors that influence the association between NE and sphingolipids in sputum from CF patients. 
Modifying Factors Sphingolipid Change in Slope Standard Error p-value 
MRSA  
Positive Culture 
Sphingomyelin d18:1/14:0 0.233 0.06406 0.0034 
Total Monohexosylceramide  0.183 0.05539 0.0064 
Monohexosylceramide d18:1/14:0 13.816 3.0586 0.0007 
Monohexosylceramide d18:1/16:0 0.367 0.09921 0.003 
Ceramide d18:1/24:0 0.591 0.2324 0.0257 
FEV1 % predicted Sphingomyelin d18:1/14:0 -0.164 0.06836 0.0318 Monohexosylceramide d18:1/14:0 -8.823 3.8738 0.0403 
Female Gender Sphingomyelin d18:1/14:0 0.282 0.07023 0.0015 Monohexosylceramide d18:1/14:0 8.105 3.6967 0.0472 
 
These data have been submitted for publication. 
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Chapter 4. Discussion 
 
 
 
 
I. Neutrophil Elastase Increased Airway Ceramide in a Mouse Model of Neutrophil Elastase-
induced Inflammation. 
Chronic infection and maladaptive, neutrophilic inflammation are characteristic of CF lung 
disease; consequently, eliminating pulmonary infections and decreasing inflammation are two of 
the primary therapeutic approaches to CF (33, 43, 144). Despite decades of research, safe and 
effective anti-inflammatory therapy remains an unmet need. NE, a neutrophil-derived protease, is 
a major contributor to lung injury and development of bronchiectasis in CF (113, 121) and 
emphysema in COPD (8). In this study, we make a novel observation: that exogenous NE increases 
the levels of ceramide in a mouse model of NE-induced, sterile inflammation. We demonstrate 
that NE specifically increases ceramide production via the de novo pathway, likely mediated via 
increased SPTLC2 protein levels. Sphingolipid metabolism is closely linked to inflammation in 
the lungs; increasing the concentration of ceramide favors the development of pathological 
inflammation (42), both in diseases with acute onset like pulmonary edema (45) as well as more 
chronic inflammatory diseases like CF and COPD (42, 94, 133). Our findings suggest that 
ceramide may mediate the induction of pro-inflammatory cytokines, whose release is stimulated 
by NE, which would be especially relevant in the context of inflammatory lung disease. Thus, the 
significance of our findings is a new paradigm of a potential self-perpetuating cycle of 
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inflammation in the CF airways: NE promotes ceramide production, which upregulates neutrophil 
chemokines, KC and HMGB1, thereby increasing neutrophilic inflammation and local NE load.  
Ceramide moieties have a broad repertoire of pro-inflammatory activities (42), and the 
properties of ceramide are dependent on fatty acid chain length (48), though this phenomenon has 
yet to be fully explored. Thus, increased synthesis of ceramide moieties of different chain lengths 
is likely an important factor contributing to inflammation. In the context of neutrophilic 
inflammation, recent studies indicate that ceramide and other bioactive sphingolipids have a 
profound effect on neutrophil migration and function (34). First, in a mouse model of multiple 
sclerosis, different pools of ceramide regulate neutrophil migration—d18:1/24:0 ceramide 
upregulates Cxcr2 mRNA expression (5), while d18:1/16:0 inhibits Cxcr2 expression and neutrophil 
adhesion (31). Moreover, both exogenous and intracellular ceramide are important for neutrophil 
phagocytic function. For example, a rise in ceramide production correlates with the culmination 
of oxidative burst (34). Conversely, introducing exogenous short chain ceramides can inhibit IgG-
induced phagocytosis (34). In our model of NE-induced inflammation, we observed increases in 
d18:1/22:0, d18:1/24:0 and d18:1/24:1 ceramide moieties, which was reflected by a statistically significant, 
2.5-fold increase in total ceramide (Figure 4). Likewise, in a mouse model of emphysema, where 
a bolus of porcine pancreatic elastase was delivered intratracheally to injure the airways, Tibboel 
et al. (2013) observed increases in d18:1/22:0, d18:1/24:0 and d18:1/24:1 ceramide. However, they also 
described increases in other, shorter chain ceramides as well as two dihydroceramides (134). Since 
myriocin, a suicide inhibitor of SPT (147), alleviated elastase-induced changes in lung function 
and the increase in BAL ceramides, authors attributed the upregulation of ceramide to de novo 
sphingolipid synthesis (134). However, they also observed changes in the expression of 
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ceramidases and acid SMase after elastase injury, over a 21-day time course. In contrast, we chose 
to focus on the enzyme responsible for the rate-limiting step of de novo ceramide synthesis: SPT. 
SPT is a critical enzyme in de novo ceramide synthesis, but its structure and subunit 
stoichiometry in mammals is still under debate (115). It is speculated that the active site(s) of SPT 
are likely formed by a heterodimer of SPTLC1 and either SPTLC2 or SPTLC3 (56). We detected 
a 2.5-fold increase in SPTLC2 protein levels at 24h after delivery of the final NE dose, compared 
to animals that aspirated vehicle control (Figure 5). We also observed a 30%, statistically 
significant decrease in SPTLC1. However, due to lack of a reliable antibody SPTLC3 was not 
assessed. The ratio of SPTLC2 to SPTLC3 within the multimeric protein may influence the 
enzymatic activity of SPT, and an increase in SPTLC2 may facilitate the production of d18:1/18:0 
and long chain ceramides, including d18:1/22:0, d18:1/24:0, and d18:1/24:1 (56). Thus, the increase in long 
chain ceramide moieties we observed is consistent with increased SPTLC2 protein and activity, 
especially as the rise in ceramide levels was noted at the same time point as increased expression 
of SPTLC2. 
Currently, the regulatory mechanisms that control SPT protein expression and activity are 
poorly defined (15, 16, 41, 89). Our data suggest that NE upregulates SPTLC2 by a post-
transcriptional mechanism, as we did not detect a change in SPTLC1 and SPTLC2 mRNA at 24h, 
or at earlier time points (Figure 6). One mechanism that could increase SPT protein is 
downregulation of microRNA miR-137, 181c, -9 or 29a/b, which would permit increased 
transcription and/or translation of SPT (41), though the former would be reflected by increases in 
mRNA. We also assessed the expression of two known modulators of SPT activity— ORMDL3 
and RTN4 (15, 16), in the lungs. Neither ORMDL3 nor RTN4 protein levels were significantly 
different when comparing animals that were administered a vehicle control versus NE (Figure 7). 
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Thus, administering NE does not appear to influence de novo sphingolipid production by 
modulating known negative regulators of SPT activity. This supports the idea that the observed 
increase in SPTLC2 affects the enzymatic activity of SPT in our mouse model of NE-induced 
inflammation. 
Pre-treating mice with myriocin, an SPT inhibitor, prior to administering NE, reduced 
ceramide expression at 24h. There was a trend towards decreased total ceramide, due to statistically 
significant decreases in d18:1/22:0 and d18:1/24:1 ceramide moieties and downward trend in d18:1/24:0 
ceramide, in mice administered myriocin prior to NE aspiration. Interestingly, pre-treatment with 
myriocin did not significantly alter the expression profile of other sphingolipids present in BAL, 
with the exception of d18:1/14:0 sphingomyelin, which was not induced by NE. Likewise, myriocin 
did not alter the expression of SPTLC2 protein in mouse lungs.  
Notably, inhibiting SPT activity using myriocin, decreased ceramide levels as well as NE-
induced expression of pro-inflammatory signaling molecules in murine BAL, including KC and 
HMGB1. Mice that were administered NE had approximately 40% neutrophils, compared to mice 
administered control vehicle which had approximately 5-10% neutrophils in BAL. However, 
neither the total number of leukocytes nor the proportion of neutrophils present in the BAL were 
significantly decreased when mice were administered an SPT inhibitor. These data corroborate the 
fact that NE can activate several signaling pathways that perpetuate neutrophil dominant airway 
inflammation (142), and while ceramide may provide yet another link between NE and cytokine 
expression, inhibiting de novo ceramide synthesis does not abrogate all of the pro-inflammatory 
effects stimulated by NE. This apparent disconnect between KC levels and neutrophil cell counts 
has been observed previously. In a model of myocardial infarction, suppression of KC using 
neutralizing antibodies did not decrease the influx of neutrophil that occurs shortly after an infarct 
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is induced (88). One possible pro-inflammatory signal that stimulates neutrophil chemotaxis in our 
model is IL33. Full length IL33 is intracellular, a non-histone DNA-binding protein that regulates 
gene expression. IL33 is released from damaged and necrotic cells and can be cleaved by 
neutrophil-derived proteases, including NE, into its mature form (69). Mature IL33, like HMGB1, 
is an alarmin and extracellular cytokine. IL33 has been detected in airway epithelium from patients 
with CF (110), and while IL33 is not directly chemotactic toward neutrophils, it potentiates 
neutrophil recruitment (4, 110). Other possible contributors that could stimulate neutrophil influx 
in our model includes bioactive lipids such as leukotriene B4 (LTB4). LTB4 is a secondary 
chemoattractant released by leukocytes, including neutrophils and macrophages, and contributes 
to both neutrophil activation and migration (2) (82). Finally, components of the complement 
system are major mediators of inflammation in a variety of diseases, and recent data indicate 
complement has a role in pulmonary inflammation in CF (50). Complement effectors C3a and 
C5a, could be involved with neutrophil influx in our model. A mouse model of pancreatic elastase-
induced abdominal aortic aneurysm demonstrated that neutrophil recruitment was dependent on 
the alternative pathway of complement activation (90). This led to production of C3a and C5a, 
which subsequently stimulated neutrophil recruitment to the site of injury (90). It is likely that 
modifying ceramide levels alone is beneficial but not sufficient to block all NE-triggered pro-
inflammatory pathways that facilitate neutrophilic inflammation in our mouse model of NE-
induced inflammation. 
There are limitations associated with this study, directing the focus of future research based 
on these data. First, we chose to focus on SPT and de novo sphingolipid biosynthesis. We have yet 
to evaluate whether NE changes expression or activity of SMases, CerS, or components of the 
salvage pathway in vivo to increase ceramide accumulation (Figure 2). SMases convert 
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sphingomyelin into ceramide. Generation of long chain ceramides, such as those we observed in 
our model, may also be due to increased expression of specific CerS. CerS are downstream of SPT 
in the de novo sphingolipid biosynthetic pathway, and are also involved in the salvage pathway 
(137). CerS2 and 5 are highly expressed in the lung (93), and CerS2 regulates the generation of 
d18:1/22:0, d18:1/24:1 and d18:1/24:0 ceramides (67, 93). Additionally, one of the major limitations of 
studying the biological effects of long chain ceramide moieties, is that there is no reliable method 
of delivering exogenous long chain ceramides into cells, due to difficulties with cellular uptake. 
On the other hand, generation of novel inhibitors that would affect the activity of specific ceramide 
synthases, thereby limiting production of ceramides of different chain lengths, would propel our 
understanding of the mechanisms further. Overall, our data support the concept that more than one 
pathway of ceramide production are stimulated by NE, as d18:1/24:0 ceramide, one of the moieties 
increased after administration of NE, trended downwards but was not significantly decreased when 
animals were pre-treated with myriocin.  
Based on the novel mechanism we describe, de novo ceramide production may be induced 
by NE in airways of patients with chronic inflammatory lung diseases. This provides novel targets 
for anti-inflammatory therapeutics. We propose that this association between NE and ceramide 
may be present in patients that suffer from acute and chronic neutrophilic inflammation in the 
lungs, such as those with CF or COPD, who demonstrate high levels of NE in airway surface fluid 
(142). Thus, in the clinical portion of this project, we sought to determine whether there is an 
association between NE activity and sphingolipid profiles in the CF airway. 
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II. Associations Between Neutrophil Elastase and Sphingolipids in Cystic Fibrosis Sputum. 
Our retrospective study of the sphingolipid content of CF sputum is the largest of its type 
in this cohort to date and is the first study investigating the association between NE and 
sphingolipids. Sputum sphingolipid levels varied among patients and with clinical status, 
demonstrating statistically significant increases in d18:1/14:0 ceramide, d18:1/24:1 ceramide, and 
d18:1/24:0 monohexosylceramide during hospitalization for CF pulmonary exacerbation. Assessing 
the levels of active NE and sphingolipid content of sputum samples, we observed a linear 
correlation between concentrations of NE and sphingolipids present in the sputum of patients with 
CF. Increasing active NE was associated with higher levels of a variety of sphingolipids in sputum, 
with statistically significant linear correlations between the levels of active NE and the 
concentrations of total sphingomyelin, ceramide, monohexosylceramide, and S1P (Figure 19). 
The greatest variety in different chain-length sphingolipids that increased with elevated NE 
activity were sphingomyelin moieties. In contrast, with ceramide, there were statistically 
significant linear correlations between active NE and d18:1/22:0 and d18:1/24:0 ceramide, both of which 
we saw increase in the BAL of our in vivo model of NE-induced inflammation. Finally, there were 
two monohexosylceramide moieties that increased with a rise in NE activity. Our study confirmed 
the existence of an association between NE and sphingolipid content in CF sputum. Taken in 
concert with published data relevant to COPD (133) and CF (13, 100), our data suggest that 
neutrophilic inflammation contributes to the abnormal sphingolipid levels observed in the lungs of 
patients with CF, possibly exacerbating an imbalance caused by CFTR dysfunction. 
The role of sphingolipids in the pathogenesis of CF lung disease in humans remains largely 
unexplored, though an association between increased ceramide and neutrophilic inflammation has 
been noted previously in CF lung tissue (13). To our knowledge, limited data are available 
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regarding the sphingolipid content in the BAL or sputum of patients with CF. Blood biomarkers 
are often preferable, due to ease of collection. Recent studies by Guilbault et al. demonstrated 
decreased ceramide in serum from CF patients, compared to healthy controls, particularly in 
d18:1/14:0, d18:1/20:1, d18:1/22:1, d18:1/24:0 ceramide moieties (49). In contrast, Brodlie et al. observed 
increased ceramide in explants of human lung tissue from CF subjects compared to non-CF 
controls (13). Also, they described an association between markers of neutrophilic inflammation 
and elevated d18:1/16:0, d18:1/18:0, and d18:1/20:0 ceramide (13). Furthermore, in CF sputum, Quinn et 
al. also observed that sphingomyelin d18:1/14:0, d18:1/15:0, d18:1/16:1, and d18:1/16:0 as well as two d18:1/16:0 
glycosphingolipids, tetraglycosylceramide and lactosylceramide, were elevated when compared to 
non-CF sputum (100). In a single subject with CF followed for 4.2 years, ceramide was increased 
during treatment of pulmonary exacerbation (99). These studies support our conclusion, that 
sphingolipids are increased locally in the CF airways, emphasizing the importance of looking at 
both systemic and local changes in sphingolipid profile in lung diseases. 
Methicillin-resistant S. aureus (MRSA) and P. aeruginosa are two of the most common 
bacterial pathogens that chronically infect CF airways. Thus, we examined whether the presence 
of MRSA and P. aeruginosa in sputum modified the association between active NE and the 
concentrations of various sphingolipids. While ceramide metabolites are critical components in 
host responses to various bacterial, viral and fungal infections (92, 117), in a recent study that 
focused on sputum metabolomics and bacteriology, Quinn et al. determined that the sputum levels 
of sphingolipids, including sphingomyelin, ceramide, and lactosylceramide, did not correlate with 
the multitude of bacterial genera they observed in the CF sputum (100). Our data revealed that the 
presence of MRSA modified the association of active NE and d18:1/14:0 sphingomyelin, d18:1/24:0 
ceramide and total monohexosylceramide— likely due to d18:1/14:0 and d18:1/16:0 
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monohexosylceramide (Table 12). The presence of MRSA in patient sputum strengthened the 
association between active NE and the concentrations of these sphingolipids. This is notable, as 
others have reported that CFTR-deficient mice are more susceptible to S. aureus infection, and that 
an imbalance between sphingosine and ceramide appears to be the culprit (131). In contrast, we 
observed no modifying effects when sputum cultures were positive for P. aeruginosa. This 
corroborates the data reported by Yu et al., in which the presence of P. aeruginosa stimulated acid 
SMase activity and ceramide synthesis in normal airway epithelial cells and wild-type mice, but 
not in CFTR-deficient cells or Cftr knockout mice (156). Cftr knockout mice are more susceptible 
to P. aeruginosa infection, possibly due to a decrease in sphingosine and increase in ceramide in 
their airways caused by lower enzymatic activity of acid ceramidase (96).  
MRSA or P. aeruginosa infection of the lungs can lead to decreased lung function, detected 
as a drop in FEV1 % predicted, indicating a flare or exacerbation of CF lung disease— a CF 
pulmonary exacerbation. FEV1 is known to be inversely associated with NE in CF (76), but, we 
wanted to determine whether patient lung function modified the association between NE and 
sphingolipids. Most of our subjects were adults with severe (FEV1<50% predicted) obstructive 
lung disease. Thus, the differences in lung function between outpatient visits and hospitalization, 
while statistically significant, were relatively small: a 5% drop in FEV1 % predicted during 
hospitalization. When the data collected from all 30 samples were analyzed using a linear mixed 
model, we observed that higher FEV1 % predicted weakened the association between NE and 
sputum sphingolipid content, i.e., the better the lung function, the weaker the association between 
active NE and d18:1/14:0 sphingomyelin and d18:1/14:0 monohexosylceramide (Table 12). 
Lastly, there are data that indicate that gender affects the progression of CF, with female 
patients having increased morbidity and shorter life expectancies (53, 129). Thus, we assessed the 
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effect of patient gender on the correlation between active NE and sphingolipids. There was an 
increased association between two sputum sphingolipids— d18:1/14:0 sphingomyelin and d18:1/14:0 
monohexosylceramide, and NE in female subjects (Table 12); the same two sphingolipid moieties 
that had stronger associations with active NE with poorer lung function. However, five out of 
seven of the female subjects participating in our study had severe lung disease, with the other two 
having moderate lung disease as defined by FEV1 % predicted criteria. Of the eight male subjects 
that provided sputum samples, three had mild, four had moderate, and only one had severe lung 
disease. Thus, it is possible the change in correlation between NE and d18:1/14:0 sphingomyelin and 
d18:1/14:0 monohexosylceramide with gender reflected the poorer lung function in female than in 
male subjects in our study. On the other hand, sphingolipids in serum and plasma are known to 
vary between genders (52). For example, healthy female subjects have increased d18:1/18:0, d18:1/22:0 
and d18:1/24:0 dihydroceramide moieties in the blood, and overall demonstrate a trend towards higher 
levels of dihydroceramides (52). The significance of these sex-related influences on sphingolipid 
and NE associations remains to be determined. As we and others (13, 99, 100) have demonstrated, 
local changes in pulmonary sphingolipid levels do not necessarily reflect those seen systemically 
(49). Thus, it is critical to determine whether there is gender-based variability in airway 
sphingolipid profiles. 
While our analysis of CF sputum demonstrates a possible relationship between active NE 
and de novo sphingolipid biosynthesis, our study has several limitations. First, the number of 
samples assessed in this study was low, with a total of fifteen subjects participating in the study. 
As all of the sputum samples in the VCU Biospecimen Repository are spontaneously expectorated, 
this limits sample availability; only a fraction of patients with CF— those with severe mutations— 
spontaneously expectorate sputum, especially when not hospitalized for CF pulmonary 
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exacerbation. Additionally, most of the subjects had severe (FEV1<50% predicted) obstructive 
lung disease, as was reflected by the low, but still statistically significant, difference in FEV1 % 
predicted when patients were hospitalized for CF pulmonary exacerbation versus outpatient visits. 
Concentrations of active NE in sputum did not differ significantly between samples collected 
during hospitalization versus outpatient visits, likely because our sputum donors had relatively 
high levels of chronic neutrophilic inflammation, as most had severe lung disease. Similar 
observations have been reported by others (105).  
 
III. Future Studies: In Vitro, In Vivo, Ex Vivo. 
Future studies will focus on mapping the signaling pathways that connect NE, 
inflammation, and sphingolipid synthesis, describing the metabolic pathways that contribute to 
NE-induced ceramide, and evaluating whether CFTR dysfunction and bacterial infection modulate 
these pathways. The presence of a strong Lipidomics Core at VCU gives our lab a unique 
opportunity; using quantitative lipidomic analyses, we can investigate sphingolipid homeostasis in 
the airways by using cellular and animal models as well as biological samples.  
Establishing an in vitro cell culture model would provide a more tractable system to 
investigate the mechanisms behind NE-induced changes in sphingolipid generation. However, 
which cell type or types are responsible for the NE-induced increases in ceramide detected in 
murine BAL, as well as those responsible for the associations between active NE and various 
sphingolipids in CF sputum, are currently unknown. Brodlie et al. potentially localized the increase 
in ceramide in the lower airways to epithelial and inflammatory cells using immunohistochemistry 
(13). The first step of establishing an in vitro model would involve determining whether the 
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sphingolipid profile observed in NE-treated cells recapitulates that of our mouse model of NE-
induced inflammation or the association observed in CF sputum. If so, we could use these cells to 
approximate NE-induced changes in sphingolipid production in the lungs.  
If we determine that NE treatment alters sphingolipid homeostasis and increases ceramide 
accumulation in differentiated cultures of primary human tracheal epithelial cells, we could 
examine whether reactive oxygen species (ROS) are required for this mechanism by inhibition of 
oxidative stress prior to and during NE treatment. NE is known to increase free iron and oxidative 
stress in airway epithelial cells (36). ROS can affect sphingolipid homeostasis by affecting both 
enzymatic activity and cellular levels of enzymes involved in sphingolipid production (72). On the 
other hand, ceramide, sphingosine, and S1P have been reported to modulate cellular redox via a 
variety of methods. For example, ceramide can stimulate NADPH oxidase activity, xanthine 
oxidase and enzymes in the mitochondrial respiratory chain to generate ROS (72).  We could also 
test whether inhibiting key enzymatic steps involved in the different pathways of ceramide 
production, using genetic silencing or pharmacologic inhibition, modulates the production of ROS, 
as well as the biosynthesis and release of pro-inflammatory chemokines and cytokines. 
More than one cell type could contribute to NE-induced changes in sphingolipid 
metabolism, and an in vitro model may prove difficult to establish. If so, we would undertake a 
more in-depth study of the pathways that contribute to the increase in ceramide induced by NE 
using our translational model. We could assess the effect of inhibiting the SMase pathway on 
ceramide production and neutrophilic inflammation in our model using desipramine. Inhibition of 
both de novo and SMase-derived ceramides could act in an additive or synergistic fashion to 
mitigate neutrophilic inflammation. Localized gene silencing using RNA interference (RNAi), by 
delivering siRNA to the lungs, could be used to verify our results with pharmacological inhibitors. 
108 
 
Appropriate methods for evaluating siRNA distribution and quantifying expression levels in tissue 
have been described previously (54). Thus, RNAi could be used to further dissect the metabolic 
pathways that contribute to the NE-induced increase in ceramide. Additionally, intranasal delivery 
of siRNA has been demonstrated in other animal models, including a rhesus macaque model used 
to study severe acute respiratory syndrome (71), and may allow for not only knockdown of SPTLC 
and SMase, but also of specific CerS. 
Finally, we have yet to investigate whether CFTR deficiency could influence NE-induced 
inflammation and airway sphingolipid levels. Administering NE to Cftr-knockout mice may 
provide a model that more closely approximates inflammation in CF lung disease. It is possible 
we would observe upregulation and downregulation of different sphingolipid species due to 
alteration in enzyme expression in Cftr-knockout mice. We could also investigate how bacterial 
infection interacts with our model of NE-induced inflammation and alters pulmonary sphingolipid 
profiles. While most bacteria do not produce sphingolipids, many are able to repurpose host-
derived sphingolipids to promote virulence (55). For example, some intracellular pathogens can 
use ceramide-enriched lipid microdomains or rafts to enter cells, while other bacteria scavenge 
sphingolipids for incorporation into their cell membranes (55, 74). Thus, we are well-positioned 
to decipher the contribution of NE, CFTR, and bacterial infection on sphingolipid homeostasis. 
Future clinical trials should include a study group of patients with CF that have a greater 
range of lung function; including healthier patients with milder mutations which would allow us 
to determine whether the severity of CFTR dysfunction affects sphingolipid expression in 
individuals. The study protocol should include sputum induction, to elicit the collection of airway 
secretions from those that do not spontaneously produce sputum. Likewise, collecting induced 
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sputum would allow for a much larger, more varied study group. Consequently, a larger future 
trial could be used to determine whether gender could affect airway sphingolipid homeostasis.  
In summary, this dissertation describes a novel mechanism that modulates inflammation 
and de novo ceramide biosynthesis in mouse lungs, induced by oropharyngeal aspiration of human 
NE. Analysis of sphingolipids in CF sputum detected a link between NE and long chain ceramide 
generation. Therefore, a similar mechanism may exist in humans: endogenous NE in CF could 
contribute to persistent inflammation in the human airway. Our results prompt a paradigm shift in 
our understanding of sphingolipid homeostasis in CF, as a novel pathway likely contributes to 
persistent airway inflammation: a potential feed-forward mechanism of neutrophilic inflammation 
and ceramide accumulation. While there is compelling published evidence that sphingolipid 
homeostasis plays an important role in innate immune function and regulation of inflammation in 
inflammatory lung diseases, the cellular sources of these effects are poorly understood. Our lab is 
positioned to further evaluate the molecular and cellular mechanisms that govern the contribution 
of NE-induced ceramide to inflammation. In aggregate, our results merit further exploration to 
elucidate biological pathways in human tissues and identify new therapeutic targets to control the 
excessive and injurious inflammation in CF lung disease.  
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